Beruflich Dokumente
Kultur Dokumente
should be avoided during breast-feeding. Assess other causes of frequent urination before
prescribing. Use with caution in patients with clinically significant bladder outflow
obstruction at risk of urinary retention, gastrointestinal obstructive disorders, risk
of decreased gastrointestinal motility, severe renal or moderate hepatic impairment
(doses not to exceed 5 mg), concomitant use of a potent CYP3A4 inhibitor, hiatus
hernia/gastroesophageal reflux and/or patients currently taking medicines that can cause or
exacerbate oesophagitis, autonomic neuropathy. QT prolongation and Torsades de Pointes
have been observed in patients with risk factors, such as pre-existing long QT syndrome and
hypokalaemia. Safety and efficacy have not yet been established in patients with
a neurogenic cause for detrusor overactivity. Patients with rare hereditary problems of
galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
should not take this medicinal product. Angioedema with airway obstruction and
anaphylactic reaction have been reported with some patients on Vesicare
. Interactions:
Concomitant medication with other medicinal products with anticholinergic properties may
result in more pronounced therapeutic effects and undesirable effects. Allow one week
after stopping Vesicare
5 mg blister packs
of 30 tablets 27.62; Vesicare
5 mg PL 00166/0197; Vesicare
10 mg
PL 00166/0198. Date of Revision: January 2013. Further information available from: Astellas
Pharma Ltd, 2000 Hillswood Drive, Chertsey, KT16 0RS. Vesicare
is a Registered Trademark.
For full prescribing information please refer to the Summary of Product Characteristics.
For medical information phone 0800 783 5018.
Date of preparation: February 2013
VES12484UK(1)
Adverse events should be reported. Reporting forms
and information can be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to Astellas Pharma Ltd.
Please contact 0800 783 5018.
www.pulsetoday.co.uk Pulse March 2013 3
c
o
v
e
r
p
i
c
t
u
r
e
:
D
r
r
o
B
e
r
t
F
r
i
e
D
L
A
N
D
,
s
c
i
e
N
c
e
p
h
o
t
o
L
i
B
r
A
r
y
/
G
i
o
v
A
N
N
i
t
A
i
t
/
A
M
A
N
D
A
o
A
k
L
e
y
/
j
o
e
D
M
i
L
e
s
March 2013
How not to miss
necrotising fasciitis
Page 50
A GPs day in photos
Page 64
We are paid less than
our salaried GP
Page 22
ThIS MONTh
6 Coverstory
Willearlierdementiadiagnosisharmpatients?
Why some GPs believe the planned case-finding DES may backfire
10 Digest
Your round-up of all the key political, finance and commissioning news
12 Contractupdate
The GPC responds to the threatened imposition
16 Clinicalround-up
All the latest guidelines, papers and policy developments
18 Investigation:WhyhasrecruitingGPsbecomesohard?
How the GP vacancy rate has quadrupled in just two years
22 Investigation:PMspracticessqueezedasfundingreviewsbite
With practices facing brutal cuts, does PMS have a future?
VIEWS
29 editorial
A profession losing its appeal
30 Feedback
Highlights from your letters and online comments
32 theBigInterview:DrPaulCundy
The GPCs IT lead on telehealth, GPES and Summary Care Records
36 Debate:CanGPsmonitorhospitalcare?
Two GPs argue for and against the Francis Inquirys recommendation
37 McCartney
on how Mid Staffs shows the folly of relying on data and box-ticking
38 Copperfeld
on whether patients are getting more stupid
70 Peverley
on how he gives scroungers short shrift
cLINIcaL
42 Keyquestionsontype2diabetes1.5CPDHoUrs
Expert answers to Dr David Russells dilemmas
44 theinformation:Bellspalsy
Two specialists advise, using PUNs and DENs
47 Picturequiz:CutaneousmanifestationsofHIv
Test your diagnostic skills
48 Practicalgenetics:Cancer1CPDHoUr
Dr Judith Hayward advises on patients with a family history of bowel cancer
50 Hownottomissnecrotisingfasciitis
Dr Adrian Boyle highlights the signs and pitfalls
YOUr PracTIcE
60 tenthingstodotoprepareforApril2013
Our GP panel on getting ready for the CQC, CCGs and the contract changes
62 Financediary:Avoidbecomingadysfunctionalpractice
Accountant Bob Senior offers tips
63 Dilemma:Aconfictofinterestbetweenpartners
What to do when one partner is a provider and another is on the CCG board
64 Workinglife:DrDavidWeinstein
A GP and a photographer revisit a photo essay that followed a 1940s doctor
4 March 2013 Pulse www.pulsetoday.co.uk
GP contract latest
Follow the very latest developments in
the GP contract talks
pulsetoday.co.uk/gpcontract
How not to miss type 1 diabetes
in children
The key signs and pitfalls in diagnosing
the condition
pulsetoday.co.uk/hntm-diabetes
Paper of the day
The best of the latest research, plus its
implications for GPs
pulsetoday.co.uk/paper-of-the-day
Dr Tom Gillham
Meet Pulses brand-new blogger
pulsetoday.co.uk/blogs
Paediatric clinic:
Intussusception
A nine-month-old boy presents to his GP with a
two-day history of non-bilious vomiting and crying
pulsetoday.co.uk/paediatric-clinic
Photo essay: Dr David Weinstein
View the full gallery of images from
a day in the life of one GP
pulsetoday.co.uk/weinstein
This months most
popular modules
Key questions on gout
1.5 CPD HOURS
Excellent module, clear with good
evidence-based references
Dr Nigel Chatwin
Clinical casebook: addiction
1.5 CPD HOURS
Excellent and very relevant to practice
Dr Maajida Ahmad
Key questions on asthma
1.5 CPD HOURS
An excellent educational module with
precise guidance for GPs
Dr Bhasker Patel
Guideline debrief: ectopic
pregnancy and miscarriage
1.5 CPD HOURS
Interesting and highly applicable
Dr Kathleen Turner
The information: plantar fasciitis
0.5 CPD HOURS
Very helpful c lear and straightforward
Dr Amanda Brown
Dont miss out join now at
pulse-learning.co.uk
pulse-learning.co.uk pulsetoday.co.uk
ONLINE-ONLY HIGHLIGHTS
You can now read
Pulse on your iPad
Over the past couple of months
weve had a fantastic response
from GPs to the new-look Pulse
magazine and one repeated
question: When are you launching
an iPad app?
Im pleased to say that we have
now done just that. Our new
interactive app enables you to
read all our trademark
investigations, analyses and
clinical features as they appear
in print, but youll be able to
do much more besides
watch embedded videos,
access further information
directly online and link up
your reading with CPD on
Pulse Learning.
The app is completely free, and
as a bonus youll get each months
Pulse as soon as its published,
before your print copy arrives
by post.
To nd out more and
download the app, go to
pulsetoday.co.uk/iPad and
as with the magazine, please
do let me know what you think
and how it can be improved at
editor@pulsetoday.co.uk
Steve Nowottny
Editor
Presentation: Betmiga
prolonged-release flm-coated
tablets containing 25mg or 50mg mirabegron. Indication:
Symptomatic treatment of urgency, increased micturition
frequency and/or urgency incontinence as may occur in adult
patients with overactive bladder (OAB) syndrome. Dosage:
Adults (including the elderly): Recommended dose: 50mg once
daily. Children and adolescents: Should not be used.
Contraindications: Hypersensitivity to active substance or
any of the excipients. Warnings and Precautions: Should
not be used in patients with end stage renal disease (or patients
requiring haemodialysis), severe hepatic impairment and severe
uncontrolled hypertension. Not recommended in patients with
severe renal impairment and/or moderate hepatic impairment
concomitantly receiving strong CYP3A inhibitors. Dose
adjustment to 25mg is recommended in patients with; mild/
moderate renal and/or mild hepatic impairment receiving
strong CYP3A inhibitor concomitantly and in patients with
severe renal and/or moderate hepatic impairment. Caution in
patients with a known history of QT prolongation or in patients
taking medicines known to prolong the QT interval. Not
recommended during pregnancy and in women of childbearing
potential not using contraception. Not recommended
during breastfeeding. Interactions: Clinically relevant drug
interactions between Betmiga
is a
moderate and time-dependent inhibitor of CYP2D6 and weak
inhibitor of CYP3A. No dose adjustment needed when
administered with CYP2D6 inhibitors or CYP2D6 poor
metabolisers. Caution if co-administered with medicines with a
narrow therapeutic index and signifcantly metabolised by
CYP2D6. When initiating in combination with digoxin, the
lowest dose for digoxin should be prescribed and serum
digoxin should be monitored and used for titration of digoxin
dose. Substances that are inducers of CYP3A or P-gp decrease
the plasma concentrations of Betmiga
. No dose adjustment is
needed for Betmiga
should be
considered when combined with sensitive P-gp substrates.
Increases in mirabegron exposure due to drug-drug interactions
may be associated with increases in pulse rate. Adverse
Effects: Urinary tract infection, tachycardia, vaginal infection,
cystitis, palpitation, atrial fbrillation, dyspepsia, gastritis, urticaria,
rash, rash macular, rash papular, pruritus, joint swelling,
vulvovaginal pruritus, blood pressure increase, liver enzymes
increase, eyelid oedema, lip oedema, leukocytoclastic vasculitis
and purpura. Prescribers should consult the Summary of Product
Characteristics in relation to other side effects. Pack and prices:
Betmiga
50mg
EU/1/12/809/008 - 014. Date of Preparation: January 2013.
Further information available from: Astellas Pharma Ltd,
2000 Hillswood Drive, Chertsey, Surrey, KT16 0RS, UK. Betmiga
is a Registered Trademark. For full prescribing information
please refer to the Summary of Product Characteristics.
For Medical Information phone 0800 783 5018.
Date of preparation: February 2013 BET13068UK
Prescribing information
Adverse events should be reported.
Reporting forms and information can
be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported
to Astellas Pharma Ltd.
Please contact 0800 783 5018
Reference:
1. Gras J. Drugs of Today 2012;48(1):2532.
N
E
W
Its time to think
of something else.
The rst in class
3
-adrenoceptor
agonist to treat the symptoms of
overactive bladder (OAB)
1
MUK147_Betmiga_290x230_AW.indd 1 13/02/2013 09:59
6 March 2013 Pulse www.pulsetoday.co.uk
cover story
this month
When he launched his challenge on
dementia a year ago, Prime Minister
David Cameron fired the starting gun on
a frantic stream of activity at the DH.
To the delight of dementia charities,
he said diagnosis and awareness levels
were shocking and accused the NHS of
collective denial over the true
prevalence of the disease.
He then tasked civil servants with
raising diagnosis rates for the condition
by 2015, with GPs at the forefront of the
plan. Now practices face a potential
3,600 cut in income if they do not sign
up to a new dementia case-finding DES
from April, funded by the retirement of
QOF indicators.
But GPs are questioning the basis of
the DES, and weighing up the pros and
cons of labelling thousands of patients
as having dementia when the services to
support them may not be in place and the
diagnosis could have far-reaching
consequences for their daily lives.
As controversy over the programme
grows, Pulse asks if the Governments
plans for dementia case-finding could
cause more harm than good.
Variation
The drive to increase diagnosis rates is
based on figures showing that only 42%
of people with dementia in England have
a formal diagnosis.
The Alzheimers Society estimates
were based on age-specific rates
determined in a review of evidence by
Kings College London and the London
School of Economics in 2007. They show
wide regional variation, with as few as
34% of the true number of cases
diagnosed in North Wales and as many
as 70% in Glasgow (see map, page 8).
A spokesperson for the charity says
the variation is due to a lack of joined-up
services: GPs want to know that there
are places they can refer to and that there
are services in place, so theres no reason
to have a nihilistic attitude.
But health secretary Jeremy Hunt has
gone much further, accusing GPs of
being unable or unwilling to diagnose
dementia, and showing a grim fatalism
that denies patients access to treatment.
In a recent article in the Daily Telegraph,
he claimed: Some even believe that
without an effective cure theres no point
putting people through the anxiety of a
memory test even though drugs can help
stave off the condition for several years.
In the Spectator, Conservative
commentator Richard Marsh claims this
emphasis on dementia is a sign of
a canny minister who knows it is
important to be seen to take action on
a disease of great public concern.
The move may be good politics, but is
it good medicine? The most recent NICE
appraisal of anticholinesterase inhibitors
concluded that they offer only small
clinical benefits for cognitive function
and have uncertain benefits for
behaviour, and there was little evidence
to support anecdotal claims they reduce
progression of dementia and delay time
to institutionalisation.
The drugs are now recommended by
NICE as options for managing mild as
well as moderate Alzheimers disease,
but as author and Alzheimers patient Sir
Terry Pratchett says, drugs for dementia
are like sandbags in the stream they
slow its progress but dont stop it.
DES specifcations
Since last March, targets to increase
diagnosis rates have been included in the
NHS outcomes framework, dementia
champions have been placed on hospital
wards and an audit of prescribing in
dementia has been launched.
But the biggest change will be in
Will earlier
dementia
diagnosis
harm
patients?
As practices prepare to take on the new dementia case-
fnding DES from April, Michael Woodhead investigates
claims widespread screening will do more harm than good
Read the draft
specifcations
for the DES
pulsetoday.co.uk/
dementia-spec
s
c
i
e
n
c
e
p
h
o
t
o
l
i
b
r
a
r
y
www.pulsetoday.co.uk Pulse March 2013 7
general practice, which will be tasked by
the new DES with screening all patients
aged 75 and over, those aged 60 and over
with risk factors, and all patients with
learning disabilities or long-term
neurological problems.
The DHs proposed specifications for
the DES due to be finalised in the next
few weeks by the NHS Commissioning
Board suggest patients should be
questioned to establish if they are
concerned about memory; then
a specific test, such as GPCog, should
be used to detect any early signs.
If a patient has suspected dementia,
GPs will be mandated to refer them to
specialist services, such as a memory
clinic, to confirm the diagnosis, then
provide treatment if necessary and give
advice and support to the patients carer.
The DH says the DES is designed to
promote early diagnosis, and insists it is
not a screening scheme.
We are suggesting GPs could deliver
a proactive approach to assessing
patients known to be at risk as a way of
improving diagnosis and care.
Controversy
The DES has proved controversial so far,
with a group of doctors, including former
RCGP president Dr Iona Heath, setting
up a petition opposing it.
They claim the DES case-finding
programme is being introduced without
any evidence of benefit and that it could
harm patients through misdiagnosis and
overtreatment, as well as distressing
patients and their families.
Dr Martin Brunet, a GP in Guildford,
Surrey, and one of the doctors leading the
petition which has 300 signatures
says the DES could confuse patients.
He says: Theres no consent, no prior
warning, which makes it quite unethical.
I think the Government and the people
promoting this are being paternalistic
and not respecting patient consent,
choices and autonomy.
The group has been invited by
dementia tsar Professor Alistair Burns to
propose an alternative way of boosting
diagnosis rates but has yet to agree on
the possible solution.
Dr Brunet says current services need
improvement, as waiting times at memory
clinics are too long and patients with
dementia dont receive adequate help, for
instance with advanced care planning or
power of attorney. He says: People
Were just
giving
someone
a label of
dementia
Dr Martin
Brunet
Expert view
Professor Steve Iliffe
GPs are right to be wary
I am not sure the scale of the problem
is as big as the Government thinks it is.
In our EVIDEM study of GP dementia
diagnosis, we are not fnding large
numbers of patients you have to do
anything with. The idea that there is
some massive unmet need is probably
not right.
I suspect some [prevalence] fgures
have been infated over time.
We are fnding a tendency to
under-document dementia in the QOF.
GPs are cautious over labelling
patients with dementia this is
understandable and may be right.
The patient may respond negatively
and it might be the last thing they want
on their records. It does close the door
to some things, particularly rehabilita-
tion services, for instance, post-stroke.
There is a lot of GP bashing over
dementia that is not warranted.
Professor Steve Iliffe, professor of
primary care for older people at
University College London and a GP in
Kilburn, north west London, is leading
the unpublished EVIDEM study
Who is likely to be
screened under the DES?
Patients aged 60 and over with CVD,
stroke, peripheral vascular disease
and diabetes
Patients with learning disabilities
Patients with long-term neurological
conditions, such as Parkinsons disease
All other patients aged 75 and over
Source: Department of Health
c
o
n
n
o
r
BMA fghts back on
contract imposition
The BMA has
fought back against
the Governments
planned imposition
of changes to the
GP contract in
England with a
31-page analysis
detailing how practices and patients will
be affected.
The official response to the
consultation published as Pulse went
to press included the results of a survey
of 8,000 GPs that found nearly 90%
believe they will be less able to provide
high-quality care as a result of the
Governments proposed contract deal for
2013/14. It also showed nearly two-thirds
of practices in England are planning to
make changes to current services
available to patients.
Overall, 30% said their practice would
have to reduce access for patients.
The BMAs analysis also said key
aspects of the contract proposal should
be delayed, including the plan to give
practices the job of paying locum
superannuation and the reduction in the
timeframe for QOF indicators from 15 to
12 months.
It argued the proposed changes work
against the thrust of the Francis Inquirys
recommendations by introducing
increasingly challenging targets for
box-ticking rather than core, holistic
patient care.
But the Department of Health was
quick to insist the changes would
focus time and money upon patient
care and have the potential to save
more lives.
Read the full story at pulsetoday.co.uk/
gpcontract
Main points of the
BMA submission
Changes to more equitable funding
between GMS and PMS practices should
not reduce the overall level of
investment and should be approved by
GPs through an opinion survey or
special conference
QOF exception-reporting guidance
should be revised, because rates are
likely to rise
Superannuation changes will have
a distorting effect on locums
The dementia DES is not supported by
evidence and contradicts NICE
There is great potential for unintended
negative consequences with plans for
making full patient records, including
test results, available online
The case-management DES will reduce
time available for routine patients
The changes will have a real impact
on recruitment and retention in general
practice
If the Government does impose the
proposals in their entirety with no
changes, do you expect your practice
to do anything differently?
What will you do?
Source: BMA survey of 6,600 partners and salaried GPs
58%
Yes
42%
No/dont know
0 10 20 30 40 50
0 10 20 30 40 50
46% expect to make administrative staff redundant
42% do not expect their practice to do anything different
30% expect to reduce access for patients
30% will reduce the use of locums
25% will reduce CCG involvement
Where do you turn when a
sulphonylurea wont do?
ONGLYZA
TM
2.5MG & 5MG FILM-COATED TABLETS (saxagliptin)
PRESCRIBING INFORMATION. Consult Summary of Product Characteristics
before prescribing.
Presentation: 2.5mg or 5mg saxagliptin (as hydrochloride) flm-coated
tablets. Indications: Adults 18 and older: For Type 2 diabetes mellitus
patients to improve glycaemic control in combination with diet, exercise:
and metformin, when metformin alone, does not provide adequate glycaemic
control; and sulphonylurea, when sulphonylurea alone does not provide
adequate glycaemic control, where metformin is considered inappropriate;
and thiazolidinedione, when thiazolidinedione alone does not provide
adequate glycaemic control and thiazolidinedione is considered appropriate;
and in combination with insulin (with or without metformin), when this
regimen alone, with diet and exercise, does not provide adequate glycaemic
control Dosage: Adults: 5mg once daily as add-on therapy with or without
food at any time of the day. Use in combination with a sulphonylurea and
insulin, consider a lower dose of sulphonylurea or insulin to reduce the
risk of hypoglycaemia. Children and Adolescents: < 18 years old: Safety
and effcacy not yet established. Moderate Hepatic Impairment: Use with
caution. Severe Hepatic Impairment: Not recommended. Moderate & Severe
renal impairment: 2.5mg once daily, caution in patients with severe renal
impairment. Assessment of renal function is recommended prior to initiation
of Onglyza, and, in keeping with routine care, renal assessment should be
done periodically thereafter. End stage renal disease: Not recommended.
Elderly: 75 years: Use with caution. Contraindications: Hypersensitivity
to saxagliptin, any of the excipients or history of a serious hypersensitivity
reaction, including anaphylactic reaction, anaphylactic shock, and
angioedema, to any dipeptidyl peptidase 4 inhibitor. Warnings and
precautions: Not for the treatment of Type 1 diabetes mellitus or diabetic
ketoacidosis. Onglyza is not a substitute for insulin in insulin-requiring
patients. Inform patients of the characteristic symptom of acute
pancreatitis: persistent, severe abdominal pain. If suspected discontinue
use of Onglyza and other potentially suspect medicinal products. If a
serious hypersensitivity reaction to saxagliptin is suspected, discontinue
use, assess for other potential causes, and institute alternative treatment.
Not recommended in patients with rare hereditary galactose intolerance,
the Lapp lactase defciency or glucose-galactose malabsorption. Limited
experience in NYHA class I-II. No experience in cardiac failure (NYHA
class III-IV) or immunocompromised patients. In keeping with routine
care, monitoring for skin disorders is recommended. Drug interactions:
Clinical data suggest low risk for clinically meaningful interactions with
co-administered medicinal products. Caution with CYP3A4/5 inducers as
glycaemic effect may be lowered. Pregnancy and lactation: Avoid use unless
clearly necessary. Undesirable events: Common adverse reactions reported
across add-on trials: Upper respiratory infection; urinary tract infection;
gastroenteritis; sinusitis; headache; and vomiting. Add-on to metformin:
Nasopharyngitis (common) Add-on to sulphonylurea: Hypoglycaemia (very
common) Add-on to thiazolidinedione: Peripheral oedema (common).
Adverse reactions reported in at least two more patients treated with
Onglyza compared to control: Add-on to metformin: Common: Dyspepsia
and myalgia. Add-on to sulphonylurea: Uncommon: dyslipidaemia and
hypertriglyceridaemia. Adverse reactions reported in post-marketing
experience: Nausea (common); pancreatitis (uncommon); hypersensitivity
reactions (uncommon); anaphylactic reactions including anaphylactic
shock (rare); angioedema (rare) and rash (common). Key: Very common
( 1/10), common ( 1/100 to <1/10), uncommon ( 1/1,000 to <1/100)
and rare ( 1/10,000 to <1/1,000). Refer to SmPC for complete information
on side effects. Legal Category: POM. Marketing authorisation number:
EU/1/09/545/012 & EU/1/09/545/006. Presentation & basic NHS price:
Onglyza 2.5mg flm-coated tablets 28: 31.60; Onglyza 5mg flm-coated
tablets 28: 31.60. Further information is available from: Bristol-Myers
Squibb / AstraZeneca EEIG, Bristol-Myers Squibb House, Uxbridge Business
Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH, UK. [ONGLYZA] is a
trademark of the Bristol-Myers Squibb / AstraZeneca group of companies.
Date of PI preparation: 09 2012 Approval code: 422UK12PM139
CV 12 0143
References:
1. Gke B et al. Int J Clin Pract 2010; 64: 1691-1631
2. Onglyza Summary of Product Characteristics
Date of preparation: January 2013
422UK13PR00414 2348001
Adverse events should be reported. Reporting forms and
information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Bristol-Myers
Squibb Pharmaceuticals Ltd. Medical Information on
0800 731 1736 or medical.information@bms.com
For your type 2 diabetes patients vulnerable to hypos, theres Onglyza
as an early add-on to metformin:
Less hypoglycaemia with comparable reduction
in HbA1c to a sulphonylurea at 1 year*
1
Onglyza 5 mg can be taken once a day,
at any time, with or without food. No need
for dose titration.
*Non-inferiority study comparing metformin and saxagliptin vs. metformin and glipizide
Onglyza 2.5 mg is suitable for patients with moderate or severe renal impairment. Caution in use with severe renal
impairment. Not recommended in ESRD requiring dialysis.
2
Nicorette Invisi Patch Prescribing Information:
Presentation: Transdermal delivery system available in 3 sizes (22.5, 13.5 and
9cm
2
) releasing 25mg, 15mg and 10mg of nicotine respectively over 16 hours.
Uses: Nicorette Invisi Patch relieves and/or prevents craving and nicotine
withdrawal symptoms associated with tobacco dependence. It is indicated
to aid smokers wishing to quit or reduce prior to quitting, to assist smokers
who are unwilling or unable to smoke, and as a safer alternative to smoking for
smokers and those around them. Nicorette Invisi Patch is indicated in pregnant
and lactating women making a quit attempt. If possible, Nicorette Invisi Patch
should be used in conjunction with a behavioural support programme. Dosage:
It is intended that the patch is worn through the waking hours (approximately
16 hours) being applied on waking and removed at bedtime. Smoking Cessation:
Adults (over 18 years of age): For best results, most smokers are recommended to
start on 25 mg / 16 hours patch (Step 1) and use one patch daily for 8 weeks. Gradual
weaning from the patch should then be initiated. One 15 mg/16 hours patch (Step
2) should be used daily for 2 weeks followed by one 10 mg/16 hours patch (Step 3)
daily for 2 weeks. Lighter smokers (i.e. those who smoke less than 10 cigarettes per
day) are recommended to start at Step 2 (15 mg) for 8 weeks and decrease the dose
to 10 mg for the fnal 4 weeks. Those who experience excessive side effects with the
25 mg patch (Step 1), which do not resolve within a few days, should change to a
15 mg patch (Step 2). This should be continued for the remainder of the 8 week
course, before stepping down to the 10 mg patch (Step 3) for 4 weeks. If symptoms
persist the advice of a healthcare professional should be sought. Adolescents
(12 to 18 years): Dose and method of use are as for adults however, recommended
treatment duration is 12 weeks. If longer treatment is required, advice from a
healthcare professional should be sought. Smoking Reduction/Pre-Quit: Smokers
are recommended to use the patch to prolong smoke-free intervals and with the
intention to reduce smoking as much as possible. Starting dose should follow the
smoking cessation instructions above i.e. 25mg (Step 1) is suitable for those who smoke
10 or more cigarettes per day and for lighter smokers are recommended to start at
Step 2 (15 mg). Smokers starting on 25mg patch should transfer to 15mg patch as soon
as cigarette consumption reduces to less than 10 cigarettes per day. A quit attempt
should be made as soon as the smoker feels ready. When making a quit attempt
smokers who have reduced to less than 10 cigarettes per day are recommended
to continue at Step 2 (15 mg) for 8 weeks and decrease the dose to 10 mg
(Step 3) for the fnal 4 weeks. Temporary Abstinence: Use a Nicorette Invisi Patch
in those situations when you cant or do not want to smoke for prolonged periods
(greater than 16 hours). For shorter periods then an alternative intermittent
dose form would be more suitable (e.g. Nicorette inhalator or gum). Smokers of
10 or more cigarettes per day are recommended to use 25mg patch and
lighter smokers are recommended to use 15mg patch. Contraindications:
Hypersensitivity. Precautions: Unstable cardiovascular disease, diabetes mellitus,
renal or hepatic impairment, phaeochromocytoma or uncontrolled hyperthyroidism,
generalised dermatological disorders. Angioedema and urticaria have been reported.
Erythema may occur. If severe or persistent, discontinue treatment. Stopping
smoking may alter the metabolism of certain drugs. Transferred dependence is
rare and less harmful and easier to break than smoking dependence. May enhance
the haemodynamic effects of, and pain response to, adenosine. Keep out of reach
and sight of children and dispose of with care. Pregnancy and lactation: Only
after consulting a healthcare professional. Side effects: Very common: itching.
Common: headache, dizziness, nausea, vomiting, GI discomfort; Erythema.
Uncommon: palpitations, urticaria. Very rare: reversible atrial fbrillation. See SPC
for further details. NHS Costs: 25mg packs of 7: (9.97); 25mg packs of 14:
(16.35); 15mg packs of 7: (9.97); 10mg packs of 7: (9.97). Legal category: GSL.
PL holder: McNeil Products Ltd, Roxborough Way, Maidenhead, Berkshire, SL6 3UG.
PL numbers: 15513/0161; 15513/0160; 15513/0159. Date of preparation:
Feb 2012.
10767_ocdnic_DPS_Pulse_290x460_fal1b.indd 1 15/02/2013 15:12
Discover A logical
combination to unlock
a smoke-free future
With sustained 16-hour background support
1
from NICORETTE
INVISIPATCH
and fast craving relief
2
from NICORETTE
+
QuickMist Mouthspray
nicotine
Adverse events should be reported.
Reporting forms and information can be
found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to
McNeil Products Limited on 01344 864 042.
Nicorette QuickMist Prescribing Information:
Presentation: oromucosal spray containing 13.2ml solution. Each 0.07 ml
contains 1 mg nicotine, corresponding to 1 mg nicotine/spray dose. Uses: Relieves
and/or prevents craving and nicotine withdrawal symptoms associated with
tobacco dependence. It is indicated to aid smokers wishing to quit or reduce prior
to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer
alternative to smoking for smokers and those around them. It is indicated in
pregnant and lactating women making a quit attempt. Dosage: Adults and
Children over 12 years of age: The patient should make every effort to stop
smoking completely during treatment with Nicorette QuickMist. One or two sprays
to be used when cigarettes normally would have been smoked or if cravings
emerge. If after the frst spray cravings are not controlled within a few minutes, a
second spray should be used. If 2 sprays are required, future doses may be
delivered as 2 consecutive sprays. Most smokers will require 1-2 sprays every
30 minutes to 1 hour. Up to 4 sprays per hour may be used; not exceeding 2 sprays
per dosing episode and 64 sprays in any 24-hour period. Nicorette QuickMist
should be used whenever the urge to smoke is felt or to prevent cravings in
situations where these are likely to occur. Smokers willing or able to stop smoking
immediately should initially replace all their cigarettes with the Nicorette QuickMist
and as soon as they are able, reduce the number of sprays used until they have
stopped completely. When making a quit attempt behavioural therapy, advice and
support will normally improve the success rate. Smokers aiming to reduce
cigarettes should use the Mouthspray, as needed, between smoking episodes to
prolong smoke-free intervals and with the intention to reduce smoking as much as
possible. Contraindications: Children under 12 years and Hypersensitivity.
Precautions: Unstable cardiovascular disease, diabetes mellitus, G.I disease,
uncontrolled hyperthyroidism, phaeochromocytoma, hepatic or renal impairment.
Stopping smoking may alter the metabolism of certain drugs. Transferred
dependence is rare and both less harmful and easier to break than smoking
dependence. May enhance the haemodynamic effects of, and pain response to,
adenosine. Keep out of reach and sight of children and dispose of with care.
Pregnancy & lactation: Only after consulting a healthcare professional. Side
effects: Very common: dysgeusia, headache, hiccups, nausea and vomiting
symptoms, dyspepsia, oral soft tissue pain and paraesthesia, stomatitis, salivary
hypersecretion, burning lips, dry mouth. Common: dizziness, paraesthesia,
palpitations, cough, aphthous stomatitis, gingival bleeding, toothache, pharyngeal
hypoaesthesia. Other: chest pain, atrial fbrillation, dyspnoea. See SPC for
further details. NHS Cost: 1 dispenser pack 11.48 2 dispenser pack 18.50.
Legal category: GSL. PL holder: McNeil Products Ltd, Roxborough Way,
Maidenhead, Berkshire, SL6 3UG. PL number: 15513/0357. Date of preparation:
Sept 2012.
References:
1. Nicorette
g
e
t
t
y
J
o
u
r
n
a
l
:
P
u
l
s
e
D
e
r
m
a
l
:
D
e
r
m
o
l
R
a
n
g
e
M
u
l
t
i
t
a
s
k
i
n
g
A
d
S
i
z
e
:
2
9
0
x
2
3
0
m
m
B
l
e
e
d
:
3
m
m
S
u
p
p
l
y
a
s
h
i
-
r
e
s
P
D
F
J
o
b
N
o
:
2
2
8
9
0
Like Jack,
Dermol can also
do two things
at once!
The Dermol family of antimicrobial
emollients - for patients of all ages who
suffer from dry and itchy skin conditions
such as atopic eczema/dermatitis.
Specially formulated to be effective and acceptable on sensitive eczema skin
Significant antimicrobial activity against MRSA and FRSA (fusidic acid-
resistant Staphylococcus aureus)
1
Over 15 million packs used by patients
2
A family of antimicrobial emollients
WASH SHOWER LOTION CREAM BATH
Dermol
Dermol
Wash, Dermol
Registered
trademark Date of last review: Nov 2012
Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard Adverse events should also be reported to Sano Pasteur MSD,
telephone number 01628 785291.
Reference: 1. Department of Health, Third Annual Report on HPV coverage. http://immunisation.dh.gov.uk/annual-hpv-
vaccine-coverage-in-england-in-201011-report/ Date accessed January 2013.
FIND THEM. REMIND THEM. HELP TO PROTECT THEM.
P
R
O
T
E
C
T
I
O
N
A
G
A
I
N
S
T
H
P
V
R
E
L
A
T
E
D
D
I
S
E
A
S
E
S
In 2010/11 over 10% of eligible girls did not start their course of HPV vaccination
to help protect against cervical cancer
1
Gardasil is available at no cost for GP practices through Movianto UK Ltd for
unvaccinated girls aged 1217
UK16362 a 02/13
BC_1548_SPMSD_UK16362 a_Gardasil GP ad update_Jan 2013_Pulse_V1_FINAL.indd 1 15/02/2013 14:27
www.pulsetoday.co.uk Pulse March 2013 21
investigation
this month
filling vacancies are also having
a financial impact. In the Pulse survey,
practices reported an average increase
in locum costs of 9.5% over the past
12 months, on top of the further
9% increase seen in 2011.
Portfolio careers
So why are so few GPs applying for
jobs? Official figures from the NHS
Information Centre show there was
a slight fall in the number of GP partners
in 2011 27,218 compared to 2001, when
there were 27,938. By contrast, the
number of consultants rose sharply from
27,782 in 2001 to 39,088 in 2011.
However, the total number of practising
GPs has increased by an average of 2.3%
annually since 2001, from 31,835 to
39,780. In other words, fewer GPs are
taking the route into partnership, instead
remaining salaried or locums. However,
unlike in 2009, when competition for
partnership vacancies was fierce, this
now seems to be through choice.
A shift towards portfolio careers and
a steadily rising number of women
choosing to work part time are both
having an impact, GPs say.
Dr Crampton says: Nobody wants
to work full time. Initially, we wanted
a nine-session partner.
What most GPs seem to want to do
now is part-time general practice and
part-time GPSI work clinical assistants,
out-of-hours work, that type of thing.
Dr Kendrick agrees partnerships are
widely seen as unattractive: There is
a lot of uncertainty about the contract
imposition, falling income and people
seeing partners working ridiculous
hours.
GPs doing other roles are now
saying: This does not look like such
an attractive option.
At the other end of the scale, GPs are
increasingly considering early retirement
as the demands of the job pile up. Exactly
half of the respondents to Pulses survey
said they were thinking of retiring early.
Many cited workload as a key reason for
considering early retirement.
Dr Swinyard says: Were seeing more
and more principals saying: Sod this, Im
going early. Some take roles working as
locums for the last few years of their
practice lives. Its a shame to lose the
wisdom of senior people you cannot
replace that.
Looking to the future
The Department of Health has recognised
that more GPs are needed for the NHS to
function, with former health secretary
Andrew Lansley last year setting out
a plan to boost the number of GP trainees
by 20% by 2015 in England so that GP
registrars would make up 50% of the
specialty training places (up from 41%).
But this drive is floundering. Figures
from the GP National Recruitment Office
(GPNRO) last summer showed there
were 2,693 GP training places accepted
in England in 2012, which actually
represented a net decrease of three
compared with the previous year.
This compares with a rise of almost
700 in hospital training places in
England, with 4,725 places accepted,
up from 4,034 in 2011. The proportion of
GP trainees fell from 40% in 2011 to 36%
in 2012.
A DH spokesman says: The DH and
Health Education England are currently
working with key stakeholders to support
the increase of training numbers in
general practice.
A national GP taskforce has been
established to support this work and
make recommendations for increasing
training posts to 3,250 each year.
An unattractive proposition
According to the Committee of General
Practice Education Directors, the
struggle to recruit new GPs is down to an
excess of hospital training places, rather
than a dearth of GP ones. Chair Dr Barry
Lewis, a GP in Rochdale, says: We have
expanded training steadily and have an
expansion target for the next three years
there is no shortage of training places.
We have empty slots in programmes,
except in London and the South East.
There are not enough applicants
because an excess of hospital specialty
posts is still in the system.
There is a significant imbalance in
the workforce at junior level that has
and continues to produce too many
-ologists and too few generalists,
especially GPs.
Research published last month
showed that only 28% of medical
graduates cite general practice as their
first-choice career, compared with 71%
who opt for secondary-care specialties.
Study leader Professor Michael
Goldacre, a professor of public health at
the University of Oxford, says there is
some cause for concern about this
relative lack of interest in general
practice from newly qualified doctors.
He says: A much smaller percentage
express a preference for a career in
general practice than the NHS actually
needs.
Rising medical school fees and the
proposed four-year training for GPs,
which could begin as soon as 2014, are
also likely to have an effect on the
numbers entering the profession.
The reluctance of many medical
graduates to opt for general practice is
not new. However, the Government is
doing a poor job of encouraging people
into the profession, says Dr Vautrey.
There is a feeling there are better
opportunities for them in hospital or
abroad, he says.
Dr Swinyard still looking to fill his
practices outstanding vacancy says
more must be done to encourage the next
generation into the profession.
General practice as a whole is looking
less attractive as a long-term career
option, he says. I still think this is the
best job in the world, but it is becoming
bloody hard to do it.
Editorial: A profession fast losing its
appeal, page 29
It has become an arms
race to get an applicant
I have found it diffcult to fll vacancies
recently. The quality of applicants and
the number has defnitely fallen.
It had been declining for a while but
it dropped dramatically in the past year.
It is a sellers market. There have
been instances where applicants have
been offered another job at the same
time elsewhere and it has become an
arms race to get that applicant in the
post by offering as attractive
a proposition as possible.
There are more people taking up
locum posts and working out of hours
in APMS providers than previously.
I dont think people want to be tied
into long-term contracts.
I think it will get worse if you want to
recruit a partner when no one knows
what is happening in three years time,
let alone fve.
Dr Richard van Mellaerts is a GP in
Kingston, Surrey
How GP vacancy rates have risen
GPs are in
a recruitment
crisis
Watch the Big
Interview with
Dr Bill Irish, chair
of the GP National
Recruitment Offce
pulsetoday.co.uk/
tbi-irish
Source: Pulse surveys and the NHS Information Centre
2.1%
2011
4.2%
2012
7.9%
2013
www.pulsetoday.co.uk 22 March 2013 Pulse
investigation
this month
In the waxing and waning fortunes of
PMS GPs, 2013 may come to be seen as
a watershed. Over the past two years,
a Pulse investigation reveals, half of such
practices have had their contracts
reviewed by managers, in the biggest
reappraisal of their funding since the
alternative GP contract was introduced.
Some report losing tens of thousands
of pounds in funding, sending GP
drawings plummeting and putting staff
at risk of redundancy. Others have gained
from the review. But most agree the
overarching purpose of the PMS contract
to provide local services has been
dumbed down by managers seeking
easy efficiency savings.
Some practices have reverted to the
GMS contract, a few have closed, but
many have had to come to terms with
new contract terms and the uncertainty
looks set to continue as the NHS
Commissioning Board begins a root-and-
branch overhaul of practice funding
from 2014.
Two-tier funding
Established as a pilot scheme in the 1997
Act for Primary Care, PMS was the first
opportunity for GPs in England to
negotiate their own contracts locally
with PCTs, based on the health needs of
their local population.
Over time, PMS contracts became
Dr Derek Hopper
explains how PMS
GPs in his area
secured their deal
pulsetoday.co.uk/
pms-negs
We are paid less than our salaried GP
We switched to a PMS contract in 2001
and our original objectives closely
matched Lambeths health needs at
that time. But last year, we were called
to a meeting.
We were given a presentation and at
the end of the meeting we were given
an envelope telling us how much we
were going to lose.
Ours was 179,000. It was a huge
chunk of our funding.
The funds cut were spent on clinical
staff and now we and our patient
access and services are hurting. We are
the second-largest practice in our
borough, with some of the highest
needs in the UK.
We have extremely high
consultation rates due to the high
disease prevalence rates, particularly
mental health issues.
We are still providing these services,
but we are having to fund it with
different methods. The clinical need
doesnt go away just because the
money goes away.
We [the partners] are now being
paid less than our salaried GP, and I
know that is not unusual because I am
part of a peer support group and it is
the same across the board.
We didnt cut the nurses pay. These
two outreach nurses were paid for by
the PMS funding, which then
disappeared. They were doing work
with frail, elderly people with long-
term conditions, just the services that
are needed now that more hospital
work is shifting to be carried out in the
community.
We are having another pay cut this
month it is going to be a reduction of
around 40%.
We do good things, but we now
have our arms tied behind our backs.
Dr Di Aitken is a GP in Lambeth, south
London
In a statement issued to Pulse, NHS
Lambeth said: Our review has given us
the opportunity to refocus and better
incentivise the provision of primary
care contracts to be more closely
aligned towards our priority health
goals which seek to address the
highest health needs in Lambeth, as
prioritised by local people and health
professionals.
One PMS practice in three has had
its contract changed in the past
two years and many are switching
back to GMS. Does PMS have
a future? Sofa Lind investigates
Pms
practices
squeezed
as funding
reviews
bite
j
O
e
d
M
I
L
e
S
Methylprednisolone BP 4%
50
+
years and still going strong
Prescribing Information
Depo-Medrone: Methylprednisolone acetate 40 mg/ml;
Depo-Medrone with Lidocaine: Methylprednisolone acetate
40 mg/ml, lidocaine hydrochloride 10 mg/ml. Please refer to the
SPC before prescribing Depo-Medrone or Depo-Medrone with
Lidocaine. Presentation: Injectable sterile aqueous suspension.
Indications: Depo-Medrone: Corticosteroid responsive conditions;
rheumatoid arthritis, SLE, Stevens-Johnson syndrome, asthma,
severe seasonal rhinitis, ulcerative colitis, Crohns disease,
osteoarthritis. Depo-Medrone with Lidocaine: Local anti-
infammatory or anti-rheumatic use where additional anaesthesia
is advantageous. Dosage and administration: Depo-Medrone:
Intramuscular, intralesional, intra-articular, periarticular, intrabursal
routes and into the tendon sheath. Dosage Range: 0.13 ml
(4120 mg). Dosing regimen depends on individual approved
indications. For full details on dosing and administration please
see Summary of Product Characteristics. Depo-Medrone with
Lidocaine: Intra-articular, periarticular, intrabursal routes and
into the tendon sheath. Dosage Range: 0.12 ml (480 mg).
Dosing regimen depends on individual approved indications. For
full details on dosing and administration please see Summary of
Product Characteristics. All aseptic precautions should be taken
and infected areas avoided. Elderly Patients: As adult dose.
Children: Dosage should be reduced for infants and children.
Contra-Indications, warnings, etc: Hypersensitivity to the
components and in the presence of systemic infections unless
specifc anti-infective therapy is employed. Neither product
should be given by the intrathecal or intravenous routes. For single
dose use only. Do not mix with other fuids. Rarely depigmentation
and skin depression occur at the injection site. Do not inject into
Achilles tendon. Intra-articular injection produces increased risk of
infammatory response in the joint. Systemic absorption from this
route can produce systemic and local effects. Some hypothalamic-
pituitary-adrenal axis suppression occurs, possibility of increased
suppression with multiple dosing. Patients should carry a Steroid
Treatment card, which gives clear guidance on the precautions
to be taken to minimise risk and which gives details of prescriber,
drug, dosage and the duration of treatment. For Depo-Medrone
only: Avoid superfcial or subcutaneous placement of intramuscular
injections. For Depo-Medrone with Lidocaine only: No
additional beneft derives from the intramuscular administration.
Use in pregnancy and lactation: Inadequate safety evidence,
balance clinical beneft against possible risk. Corticosteroids
are excreted in breast milk. Use in children: Corticosteroids can
cause growth retardation. Side-effects: Known corticosteroid
effects may be observed. Some of the serious side effects that
may occur include: Anaphylactic reaction, peptic ulceration with
perforation and haemorrhage, acute pancreatitis, congestive heart
failure, hypertension, psychiatric reactions (e.g. suicidal thoughts)
and psychotic reactions (e.g. mania, delusions). For full details on
all other side effects please see SPC Package quantities: 1, 2
and 3 ml vials. Depo-Medrone with Lidocaine: 1 ml and 2 ml
vials only. Basic NHS cost: Depo-Medrone Injection 1 ml 3.44.
Depo-Medrone Injection 1 ml x 10 34.04. Depo-Medrone
Injection 2 ml 6.18. Depo-Medrone Injection 2 ml x 10 61.39.
Depo-Medrone Injection 3 ml 8.96. Depo-Medrone 3 ml x 10
88.81. Depo-Medrone + Lidocaine Injection 1 ml 3.94.
Depo-Medrone + Lidocaine Injection 1 ml x 10 38.88.
Depo-Medrone + Lidocaine Injection 2 ml 7.06. Depo-Medrone +
Lidocaine Injection 2 ml x 10 70.13. Product licence numbers:
Depo-Medrone: PL 00032/5038R. Depo-Medrone with
Lidocaine: PL 00057/0964. Marketing authorization
holder: Depo-Medrone: Pharmacia Limited, Ramsgate Road,
Sandwich, Kent CT13 9NJ, UK. Depo-Medrone with
Lidocaine: Pfzer Limited, Ramsgate Road, Sandwich, Kent
CT13 9NJ, UK. Legal Category: POM. Further information
is available on request from: Medical Information at
Pfzer Limited, Walton Oaks, Dorking Road, Tadworth, Surrey,
KT20 7NS, UK. Tel: +44 (0) 1304 616161. Date of preparation:
March 2012. Ref: DM + DM+L 4_5 UK
Adverse events should be reported.
Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to
Pfzer Medical Information on 01304 616161
w
w
w
.
d
e
p
o
m
e
d
r
o
n
e
.
c
o
.
u
k
Date of preparation: April 2012 UK/MED/12/0006
www.pulsetoday.co.uk 24 March 2013 Pulse
investigation
this month
M
P
3
5
8
Still the only preservative-free single unit dose
eye drops for the relief of allergy symtoms
Available on prescription
www.moorfeldspharmaceuticals.co.uk
+44 (0)20 7684 9090 (option 1)
Adverse events should be reported. Reporting forms and
information can be found at www.yellowcard.gov.uk/
Adverse events should also be reported to Moorfelds
Pharmaceuticals on 020 7684 9090 (option 1).
CATACROM
0.03%
ointment (tacrolimus monohydrate) Protopic
0.1% ointment
(tacrolimus monohydrate) ACTIVE INGREDIENT Protopic
0.03% ointment (1g) contains 0.3mg of tacrolimus as
tacrolimus monohydrate (0.03%). Protopic
0.1% ointment
(1g) contains 1.0mg of tacrolimus as tacrolimus monohydrate
(0.1%). THERAPEUTIC INDICATIONS Protopic
0.03%:
- treatment of moderate to severe atopic dermatitis in children
(2 years of age and above) who failed to respond adequately
to conventional therapies such as topical corticosteroids. -
treatment of moderate to severe atopic dermatitis in adults
who are not adequately responsive to or are intolerant of
conventional therapies such as topical corticosteroids.
Protopic
can
be used for short-term and intermittent long-term treatment.
Treatment should not be continuous on a long term basis.
Protopic
should not
be applied under occlusion. Protopic
0.1% is
not indicated for use in children. Treatment with Protopic
0.03% should be started twice a day for up to three weeks.
Afterwards the frequency of application should be reduced to
once a day until clearance of the lesion. Use in adults (16 years
of age and above) Treatment should be started with Protopic
0.1% twice a day and continued until clearance of the lesion. If
symptoms recur, twice daily treatment with Protopic
0.1%
should be restarted. An attempt should be made to reduce the
frequency of application or use the lower strength if the clinical
condition allows. Generally, improvement is seen within one
week of starting treatment. If no signs of improvement are
seen after two weeks of treatment, further treatment options
should be considered. Maintenance of fare-free intervals:
Protopic
0.1%,
children (2 years of age and above) should use the lower
strength Protopic
.
Patients should be advised on appropriate sun protection
methods, such as minimisation of the time in the sun, use of a
sunscreen product and covering of the skin with appropriate
clothing. Protopic
to
patients with extensive skin involvement over an extended
period of time, especially in children. Patients, particularly
paediatric patients should be continuously evaluated during
treatment with respect to the response to treatment and the
continuing need for treatment. After 12 months this evaluation
should include suspension of Protopic
treatment in paediatric
patients. The potential for local immunosuppression
(possibly resulting in infections or cutaneous malignancies) in
the long term (i.e. over a period of years) is unknown.
Protopic
should be
considered. The effect of treatment with Protopic
on the
developing immune system of children aged below 2 years has
not been established. Before commencing treatment with
Protopic
should not be
used during pregnancy unless clearly necessary and is not
recommended when breast-feeding. Protopic
is unlikely to
have an effect on the ability to drive or use machines.
CONTRAINDICATIONS Hypersensitivity to macrolides in
general, to tacrolimus or to any of the excipients.
INTERACTIONS Paediatric population:- An interaction study
with protein-conjugated vaccine against Neisseria menigitidis
serogroup C has been investigated in children aged 2-11 years.
No effect on immediate response to vaccination, the generation
of immune memory, or humoral and cell-mediated immunity
has been observed. Systemically available tacrolimus is
metabolised via the hepatic Cytochrome P450 3A4. The
possibility of interactions cannot be ruled out and the
concomitant systemic administration of known CYP3A4
inhibitors in patients with widespread and/or erythrodermic
disease should be done with caution. PACKAGE SIZES
Prices exclude VAT: Protopic
0.1% ointment
21.60 (30g tube), 39.40 (60g tube) LEGAL
CATEGORY: POM. MARKETING AUTHORISATION
NUMBERS Protopic
Gel (Felbinac)
Presentation: Traxam Gel 3% w/w is a clear, non-greasy, non-staining gel
containing 30mg felbinac in each gram. Indication: Topical anti-infammatory
and analgesic for the relief of rheumatic pain, pain of non-serious arthritic
conditions and soft tissue injuries such as sprains, strains and contusions.
Dosage and Administration: Cutaneous administration. In adults and elderly:
Rub 1g Traxam Gel (approximately 1 inch/2.5cm of gel) lightly into the affected
area(s) 2 to 4 times a day. Do not exceed total daily dose of 25g regardless of
the size or number of affected areas. Children: Not recommended. Wash hands
following application unless they are the site of treatment. Contraindications:
Hypersensitivity to the ingredients. Patients in whom attacks of asthma, urticaria
or acute rhinitis are precipitated by aspirin or other non-
steroidal anti-infammatory drugs. Special Precautions
and Warnings: Use of Traxam should be limited to intact
and non diseased skin and it should not be applied with
occlusive dressings, or simultaneously to the same site
as other topical preparations. Discontinue if rash develops. Contact with mucous
membranes and the eyes should be avoided. Topical application of large amounts
may result in systemic effects, such as hypersensitivity, asthma and renal disease.
To avoid the possibility of photosensitivity, patients should be advised against
excessive exposure of treated areas to sunlight. Pregnancy and Lactation:
Not recommended. Interactions: Serum levels following topical application are
extremely low and therefore clinical drug interactions are unlikely. Concurrent use
of aspirin or other NSAIDs may result in increased incidence of adverse reactions.
Adverse Effects: The overall incidence of side effects reported with Traxam Gel
is low (less than 2%). Anaphylaxis, respiratory reactivity comprising asthma,
aggravated asthma or dyspnoea, purpura, angioedema, bullous dermatoses
(including epidermal necrolysis and erythema multiforme) and skin photosensitivity
have been reported. Local reactions such as mild erythema, irritation, dermatitis;
pruritus and paraesthesia which recover upon cessation of treatment may be
seen with Traxam Gel/Foam. Whilst systemic side effects are rare; gastrointestinal
disturbances and hypersensitivity reactions such as rashes and bronchospasm
have been reported. Please refer Summary of Product Characteristics for
detailed information. Legal Category: POM. Basic NHS Cost: 100gm gel 8.03.
Marketing Authorisation Numbers: PL 12762/0085. Marketing Authorisation
Holder: Mercury Pharmaceuticals Ltd., NLA Tower, 12-16 Addiscombe Road,
Croydon, Surrey; CR0 0XT, UK. Date of preparation: July 2012.
Adverse events should be reported to the local regulatory
authority. Reporting forms and information can be found at
http://yellowcard.mhra.gov.uk. Adverse events should also
be reported to Mercury Pharma Medical Information
at 08700 70 30 33 or via e-mail to
medicalinformation@mercurypharma.com
Visit www.managingpain.co.uk for more information.
UK/TRA/ADV/194/2012 Date of preparation: July 2012.
At their age
youd think
theyd know
better...
...fortunately
for them theres
Relieves pain and Relieves pain and
infammation infammation
G
E
L
100482 MER Pulse Traxam Ad (290x230) AW.indd 1 26/11/2012 16:32
Its time to take IBS seriously
UKLIN1616 January 2013
Irritable Bowel
Syndrome
Painful, distressing, exhausting
Irritable Bowel Syndrome is a physical disorder associated
with multiple symptoms that include chronic abdominal pain,
bloating and either constipation (IBS-C), diarrhoea (IBS-D) or
mixed symptoms of diarrhoea and constipation (IBS-M).
In other words, IBS has a much more serious effect on patients
lives than you might think.
J
o
b
N
o
:
A
L
M
0
1
J
1
2
0
0
5
_
M
a
r
k
e
t
_
S
h
a
p
i
n
g
_
P
U
L
S
E
_
2
9
0
x
2
3
0
S
i
z
e
:
2
9
0
x
2
3
0
m
m
1
A
B
P
I
:
T
Y
P
E
F
A
C
E
:
I
M
A
G
E
S
H
R
:
L
R
:
C
M
Y
K
:
S
P
O
T
:
S
c
i
e
n
c
e
w
r
i
t
e
r
:
D
e
s
i
g
n
:
A
r
t
D
i
r
:
C
r
e
a
t
.
D
i
r
:
C
o
p
y
w
r
i
t
e
r
/
P
r
o
o
f
:
S
.
M
a
n
:
A
c
c
.
M
a
n
:
A
c
c
.
D
i
r
:
ALM01J12005_Market_Shaping_PULSE_290x230.indd 1 31/01/2013 12:05
www.pulsetoday.co.uk Pulse March 2013 29
EDITORIAL
I
ts been widely accepted for some time now
that general practice needs more GPs. The
shift of work from secondary to primary care
is an ongoing trend, the retirement time
bomb seems to have been ticking for years
and the small matter of GPs taking on
commissioning responsibility, now just four
weeks away, has been on the horizon since 2010. But
our investigation this month suggests long-standing
fears of a recruitment crisis have finally been
realised, with the average vacancy rate for GP posts
at practices quadrupling in just two years.
It is important, of course, not to overstate the case.
An average vacancy rate is a crude measure which
masks regional variation, and there have always been
cyclical fluctuations in the jobs market. Just a few
years ago, we were talking about a recruitment crisis
in general practice which consisted of there being too
few jobs for GPs, rather than the other way round.
Its also worth acknowledging the shortages are
partly due to general practices rapidly changing
demographics. 2013 is supposed to be the year when
women will for the first time make up the majority of
the GP workforce, but its not just female GPs who are
increasingly keen on a better work-life balance.
Portfolio careers, meanwhile, are fast becoming the
norm. Dr David Weinstein, for instance, the Brighton
GP featured in our Working Life photo essay this
month (page 64), works every Friday in A&E and
says the variety makes him a better doctor.
Whatever the causes, both CCGs and the
Department of Health must do more to ensure
practices can plug the gaps. Adequate backfill for
partners taking on commissioning work and
including sessional GPs in CCG work will help
somewhat; asking practices to pay locums
superannuation and then reimbursing them
according to list size rather than locum use,
as is currently the plan, will probably not.
But beyond the immediate difficulties in filling
vacancies, the jobs crisis raises fundamental
questions about the future of the profession, a nd how
it can attract the new blood it desperately needs.
General practice has always been a hard sell to
medical graduates tempted by the glamour of hospital
medicine, but in the years after the introduction of the
2004 contract, healthy earnings, acceptable hours and
a degree of independence
made it an attractive
alternative. Yet, despite the
DH boldly declaring that
GP registrars should
account for 50% of
specialty training places by
2015 and opening up more
training slots as a result,
deaneries are struggling to
fill the ones they have.
If ministers are serious
about increasing the
number of GPs, they must make it an enticing
career option once again. GPs cite an unmanageable
workload and box-ticking clinical culture as
off-putting factors for would-be trainees, while
increasing bureaucracy and contractual uncertainty
are dissuading many from the financial commitment
of partnership. In the past few months alone,
ministers have brought in revalidation, ripped up
the GP contract and gone to war over pensions.
If they really do value general practice, they have
a funny way of showing it.
For an older generation general practice will
always be, as Dr Peter Swinyard puts it, the best job
in the world. But that generation is a retiring breed.
Their successors need to know it will still be the best
job in the world in 20 years time.
A profession fast
losing its appeal
Email
pulse@pulsetoday.co.uk
Address (editorial)
Pulse,
Brieng Media, 3rd Floor
Mermaid House,
2 Puddle Dock,
London
EC4V 3DB
Group editor
Jo Haynes
Editor
Steve Nowottny
Group clinical editor
Adam Legge
Deputy editor
Nigel Praities
Senior journalist
Jaimie Kaffash
Senior journalist
Soa Lind
Journalist
Madlen Davies
Digital content
manager
Jessica Baron
Online intern
Cat Atteld
Deputy clinical editor
Rhiannon Smith
Assistant clinical editor
David Swan
Assistant features
editor
Ellie Broughton
Art director
Ravi Naidoo
Art editor
James Depree
Editorial adviser
Dr Keith Hopcroft
Production controller
Justine Sumner
Classied executive
Cliff Brown
Key account manager
George Haddad
Key account manager
Richard Springham
Projects director
Paul Berressem
Commercial director
Sanjay Chudasama
CEO, Brieng Media
Neil Thackray
CMO, Brieng Media
Rory Brown
Editorial enquiries
020 7332 2904
Classied advertising
020 7332 2924
Display advertising
020 7332 2928
pulsetoday.co.uk
020 7332 2938
Delivery and
subscription
Medical Reader, c/o
BHP, 2-3 Commercial
Way, Christy Close,
Southelds, Basildon
SS15 6EF
Free circulation:
Call 0845 1369316
or email
medicalreader@
binleys.com
Paid subscription:
Call 0844 543 8022
Registered ofce
Brieng Media, 3rd
Floor Mermaid House,
2 Puddle Dock, London
EC4V 3DB
Brieng Media 2013
All rights reserved.
No part of this
publication may be
reproduced or
transmitted in any form
or by any means,
electronic or mechanical
including photocopying,
recording or any
information storage or
retrieval system without
the express prior written
consent of the publisher.
The contents of Pulse
are subject to
reproduction in
information storage and
retrieval systems.
Pulse is available on
subscription at 160 per
year (single copy 16).
Overseas subscriptions,
including Europe, $327
per year (single copy
$41). Refunds on
cancelled subscriptions
will only be provided at
the publishers
discretion, unless
specically guaranteed
within the terms of
subscription offer.
Brieng Media may pass
suitable reader
addresses to other
relevant suppliers.
If you do not wish to
receive sales
information from other
companies, please write
to Pulse, Brieng Media,
3rd Floor Mermaid
House, 2 Puddle Dock,
London EC4V 3DB.
Printed by Headley
Brothers, The Invicta
Press, Ashford, Kent
If ministers
really do value
GPs, they have
a funny way of
showing it
V
I
E
W
S
Steve Nowottny,
Pulse editor
Dovobet Gel: Topical treatment of scalp psoriasis in adults. Topical
treatment of mild-to-moderate non-scalp plaque psoriasis vulgaris in
adults. Dovobet Ointment (calcipotriol/betamethasone dipropionate):
Treatment of stable plaque psoriasis vulgaris amenable to topical therapy
in adults. Please consult the Summary of Product Characteristics before
prescribing, particularly in relation to side-effects, precautions and
contraindications. POM. Further information is available on request from
the marketing authorisation holder: LEO Pharma, Longwick Road, Princes
Risborough, Bucks HP27 9RR. LEO LEO Pharma, UK. All LEO trademarks
mentioned belong to the LEO Group. Code 1008/11053 January 2013.
Adverse events should be reported. Reporting forms and information
can be found at: www.mhra.gov.uk/yellowcard. Adverse events
should also be reported to Drug Safety at LEO Pharma by calling
01844 347333.
Compare ointment and gel for
yourself. Order vehicle samples
today www.dovobetgel.co.uk
Its about time you saw the dierence
28664 Dovobet Half Horizontal Pulse Ad v8 AW.indd 1 01/02/2013 11:50
www.pulsetoday.co.uk 30 March 2013 Pulse
GPs must consider
new ways of working
in order to survive
From Dr Malcolm Ridgway, Blackburn
I think all GPs are aware of the extra
stress on practices and the likely further
increases in demand and reductions in
income (Shocking numbers of GPs
seeking pastoral support, say LMCs,
pulsetoday.co.uk/news).
For me, we are trying to utilise
a general practice model that was
invented before the inception of the
NHS to deliver 21st-century care. Many
commentators (such as the Kings Fund)
are now calling for the cottage industry/
corner shop organisational model of
general practice to be updated. The
RCGP has talked about federation. The
Government, I think, is piling on the
pressure to enforce structural changes
voluntarily or GPs will have to
surrender and succumb to an enforced
salaried model, vertical integration or
whatever scheme seems politically
beneficial at the time.
I always feel we should be in control of
our own destiny, yet all I see from GP
colleagues is a head-in-the-sand, hope it
all goes away or I retire attitude. When
will we wake up and smell the coffee?
There are possible models that maintain
continuity of care, improve quality and
reduce variation, maintain practice
sovereignty, expand and improve
services, bring more expertise and care
out into the community and yet improve
work-life balance and maintain incomes.
Successful businesses generally expand
and diversify (like Google and Tesco) and,
at the end of the day, GP practices are
businesses at least for now. Yet the vast
majority of GPs wont even consider
alternative models of working.
I think Pulse should start a campaign
that debates innovative solutions to do
what I have said above, and at least gets
GPs thinking outside the box. I am close
to retirement, so none of this will really
affect me, but I am getting fed up with
the increasingly intense demands from
clinical work. Also, I have seen lots of
GPs of my age or younger retiring not
because they feel able to financially, but
because they can no longer cope with
how general practice has become. These
are people at the height of their
experience and knowledge and they will
be sadly missed by their patients, and
indeed the NHS.
From Dr Ivan Camphor, secretary of
Mid Mersey LMC, via pulsetoday.co.uk
General practice is going through
exceptionally challenging times. Morale
is at an all-time low, and we are all
suffering from overload. I work 12-hour
days in the week and spend all Sunday,
like colleagues, doing paperwork. Were
only human, and we need to see our
families and friends to survive
emotionally. At the moment GPs are
maxed out many of my colleagues in
their 50s are retiring simply to get away
from the workload. General practice isnt
sustainable at the moment which
makes the failure of the latest contract
negotiations all the more painful to
watch.
We must fnd
alternative
models for
general
practice
Come to Pulse
Live, your
one-stop annual
event to debate
the future of
general practice
pulse-live.co.uk
Could GPs learn business lessons from Tesco?
Letter of the month
Feedback
Views
Email: letters@pulsetoday.co.uk
Lets call ministers
bluff and resign from
CCGs en masse
From Dr Anthony OBrien, Silverton, Devon
Why is the GPC not suggesting
co-ordinated action in response to the
contract imposition? We have a powerful
negotiating weapon that we seem to be
ignoring. A co-ordinated resignation of
practices from CCGs would have no effect
on patients or doctors but would cause
apoplexy in Government and Whitehall.
It is surprising that GPs who have been
coerced into commissioning are not now
questioning whether we wish to continue
our involvement. Why should we help
the Government with its NHS rationing
difficulties? The Government cannot
allow its commissioning project to fail.
But CCGs are membership organisations.
The statutory duty to belong to a CCG
may be part of the new contract but it is
not in the old one.
If we resign from our CCGs, political
chaos will follow. The Government will
be forced back to the negotiating table.
The public will not be affected and will
have no understanding of what is
happening. We will not be seen to be
complaining about money just
reconsidering the flawed health bill
proposals. Commissioning enthusiasts
might have to twiddle their thumbs for
a bit, but we have survived without fully
functioning PCTs for many months.
A few more will not sink the NHS.
If practices want to leave CCGs, they
do not have to justify themselves. If the
Government wishes to use the courts to
impose the contract and commissioning,
we should challenge them to do so. It is
important to emphasise this is not a
debate about money or pros and cons of
commissioning. It is a point of principle.
We have negotiated in good faith and do
not wish to be treated in this way.
Shame on the GPC for being so
despondent. We should all stand up,
stop moaning and call for a boycott of
commissioning if negotiations are not
reopened.
Common sense
approach to CSA
must stay
From Dr Hamish
Duncan, Exeter, via
pulsetoday.co.uk
While it is laudable
to ensure the CSA
exam is rigorous and
non-discriminatory,
lets not create a two-tier
pass rate (Lawyers give RCGP three
weeks to sort CSA, or face legal action,
pulsetoday.co.uk/news). a
l
a
M
y
x
2
Dovobet Gel: Topical treatment of scalp psoriasis in adults. Topical
treatment of mild-to-moderate non-scalp plaque psoriasis vulgaris in
adults. Dovobet Ointment (calcipotriol/betamethasone dipropionate):
Treatment of stable plaque psoriasis vulgaris amenable to topical therapy
in adults. Please consult the Summary of Product Characteristics before
prescribing, particularly in relation to side-effects, precautions and
contraindications. POM. Further information is available on request from
the marketing authorisation holder: LEO Pharma, Longwick Road, Princes
Risborough, Bucks HP27 9RR. LEO LEO Pharma, UK. All LEO trademarks
mentioned belong to the LEO Group. Code 1008/11053 January 2013.
Adverse events should be reported. Reporting forms and information
can be found at: www.mhra.gov.uk/yellowcard. Adverse events
should also be reported to Drug Safety at LEO Pharma by calling
01844 347333.
Compare ointment and gel for
yourself. Order vehicle samples
today www.dovobetgel.co.uk
Its about time you saw the dierence
28664 Dovobet Half Horizontal Pulse Ad v8 AW.indd 1 01/02/2013 11:50
What youre saying
about the Francis
Inquiry
We do not need GPs
to be given the role
of assessing care
standards. We need
to use existing
processes properly
The concept of
a primary care-led NHS
was always just wishful
thinking easily said
but never done
And there was me
thinking the CQC
actually had a purpose
Join the debate at
pulsetoday.co.uk/your-comments
Join the debate
Have your say on
the big GP issues of
the moment at
pulsetoday.co.uk/
forum
Being a good doctor includes a certain
level of understanding of the cultural and
linguistic norms of the society you serve,
the systems to deliver the service and the
ability to work within a different cultural
context. If someone is not good enough
to do this, they should fail regardless of
background. Multiple failings should
lead to removal from training. There is
nothing politically incorrect, racially
motivated or immoral about this, its just
good common sense.
In the same vein, lets ensure this
challenge is rigorous and sensible and
the outcome does not succumb to
political correctness. If the verdict goes
against the plaintiffs, they must accept it
and move on. If it finds in favour, the
RCGP needs to answer serious questions
about its impartiality and conduct.
How many GPs does
it take to change
a lightbulb?
From Dr Gavin Jamie, Swindon,
via pulsetoday.co.uk
Your story (CCG calls GPs into crisis
point hospital to help assess every
patient for discharge, pulsetoday.co.uk/
news), reminded me of a joke on Twitter
a few weeks ago: Q: How many National
Rifle Association members does it take to
change a lightbulb? A: More guns!
It sometimes seems the reflex answer
to any issue in health is More GPs!
While this faith in our omnipotence is
touching, it may be seen by others as
arrogance or even pomposity. Hospitals
are full of excellent doctors capable of
making good assessments of their
patients. Could they benefit from more
knowledge of community care? Quite
possibly. But lets respect them, let them
do their job and fund decent and prompt
community care.
Feedback
32 March 2013 Pulse www.pulsetoday.co.uk
Views
The BiG iNTeRView
Dr Paul Cundy
its time to
pull the plug
on summary
Care Records
Does the NHS IT programme promise genuine progress
or just change for its own sake? Madlen Davies talks to the
GPCs IT lead Dr Paul Cundy
In this practice we have a disproportionate
number of nuns, begins Dr Paul Cundy,
in answer to a question about concerns
over data requests from the new General
Practice Extraction Service (GPES), the
Government-run system that is set to
make patient records more accessible to
NHS managers, researchers and private
companies.
We have concerns that some queries
might not be appropriate for those
patients.
It is a typically clear-headed response,
sensitive to the real-world concerns of
patients, to a question about the use of IT,
for which he has been a GPC
spokesperson for nearly 12 years.
Sitting in his surprisingly low-tech
practice in Wimbledon, south-west
London, Dr Cundy appears relaxed,
despite the continual stream of new-
technology projects clogging up his
in-tray as they float downstream from
the Department of Health.
A member of the GPC for 18 years and
a GP since 1982, Dr Cundy has seen his
fair share of politicians promising
whizz-bang technology solutions that
turn out to be duds.
And this Government, he says, is no
different.
Its a continuing disappointment
that successive governments have
introduced policy that is not based on
evidence, he says with an air of weariness.
Thats the political world, its not the
scientific world we live in. The GPC will
point out the evidence; its up to the
Government to decide whether to listen.
Online records
Dr Cundy is leading the GPCs IT
subcommittee at a time when historic
decisions are being made about the
future of NHS IT. Health secretary Jeremy
Hunt who has promised a paperless
NHS by 2018 has made technology a top
priority, with the Governments
information strategy aiming to enable
patients to book GP appointments, access
their records and contact their GP online
by 2015.
Dr Cundy says these proposals for GPs
are self-evidently very sensible but need
to be carefully managed: The net effect
will lower the threshold at which
patients will communicate with health
services; that will inevitably result in an
increase in workload.
If general practice suffers what has
happened in the States, where theres
a 25% across-the-board increase in work,
primary care will fall apart because it
cannot sustain that level of increase.
Summary Care Records
He is even more strident on the long-
running Summary Care Record (SCR)
Choose and Book
is an absolute
nightmare
Watch the full
interview with
Dr Paul Cundy
pulsetoday.co.uk/
tbi-cundy
CV
Chair of the GPC
IT subcommittee
since 1999 (bar
two years)
GP in
Wimbledon,
south-west
London, since
1982
Ran a GP
out-of-hours
commissioning
group for 10 years
Ran an IT
company for
15 years
Lists motor
racing, fying
planes and
anything
mechanical as his
hobbies
SR and PALEXIA
Prescribing Information.
Refer to the Summary of Product Characteristics (SmPCs) before prescribing. Presentation:
Palexia SR: 50 mg (white), 100 mg (pale yellow), 150 mg (pale pink), 200 mg (pale orange)
and 250 mg (brownish red) prolonged-release tablets contain 50 mg, 100 mg, 150 mg,
200 mg and 250 mg of tapentadol (as hydrochloride) respectively. Palexia: 50 mg (white)
and 75 mg (pale yellow) flm-coated tablets contain 50 mg and 75 mg of tapentadol (as
hydrochloride) respectively. Indication: Palexia SR is indicated for the management of
severe chronic pain in adults, which can be adequately managed only with opioid analgesics.
Palexia is indicated for the relief of moderate to severe acute pain in adults, which can be
adequately managed only with opioid analgesics. Dosage and method of administration:
Individualise according to severity of pain, the previous treatment experience and the
ability to monitor the patient. Swallowed whole with suffcient liquid, with or without food.
Palexia SR should not be divided or chewed. Palexia SR dosage: Initial dose 50 mg twice
a day. Switching from other opioids may require higher initial doses. Titrate in increments
of 50 mg twice a day every 3 days for adequate pain control. Total daily doses greater
than 500 mg not recommended. Palexia dosage: Initial dose 50 mg every 4 to 6 hours.
On the frst day of dosing, an additional dose may be taken 1 hour after the initial dose, if
no pain control. The frst days dose should not exceed 700 mg. Maximum maintenance
daily dose of up to 600 mg. Discontinuation of treatment: Taper dose gradually to prevent
withdrawal symptoms. Renal/hepatic impairment: Not recommended in severe patients.
Caution and dose adjustments with moderate hepatic impairment. Elderly: May need
dose adjustments. Children below 18 years: Not recommended. Contraindications:
Hypersensitivity to ingredients, suspected or having paralytic ileus, acute alcohol
intoxication, hypnotics, centrally acting analgesics or psychotropics. Not for use when
mu-opioid receptor agonists are contraindicated (e.g. signifcant respiratory depression,
acute or severe bronchial asthma or hypercapnia). Special warnings and precautions:
At risk patients may require monitoring due to misuse, abuse, addiction or diversion.
At high doses or in mu-opioid receptor agonist sensitive patients, dose-related respiratory
depression may occur. Caution and monitoring required with impaired respiratory function.
Should not use in patients susceptible to intracranial effects of carbon dioxide retention (e.g.
increased intracranial pressure, impaired consciousness or coma). Use with caution with head
injury, brain tumors, history or at risk of seizures, moderate hepatic impairment, biliary tract
disease or acute pancreatitis. Not recommended with severe renal or hepatic impairment.
Avoid use in patients who have taken monoamine oxidase inhibitors (MAOIs) within the last
14 days, due to cardiovascular events. Should not use with hereditary problems of galactose
intolerance, Lapp lactase defciency or glucose-galactose malabsorption. Interactions: Use
with benzodiazepines, barbiturates and opioid analgesics, antitussive drugs and substitutive
treatments may enhance the risk of respiratory depression. Central nervous system (CNS)
depressants (e.g. benzodiazepines, antipsychotics, H1-antihistamines, opioids, alcohol) can
enhance the sedative effect and impair vigilance. Consider dose reduction with respiratory or
CNS depressant agents. In isolated cases, serotonin syndrome has been reported with Palexia
SR/Palexia in combination with serotoninergic medicinal products (e.g. serotonin
re-uptake inhibitors). Care should be taken with mixed mu-opioid agonist/antagonists
or partial mu-opioid agonists due to risk of reducing the analgesic effect. Use
with strong inhibitors of uridine diphosphate transferase isoenzymes (involved in
glucuronidation) may increase systemic exposure of Palexia SR/Palexia. Risk of
decreased effcacy or adverse events if used with strong enzyme inducing drugs
(e.g. rifampicin, phenobarbital, St Johns Wort). Pregnancy and lactation: Do not use.
Driving and using machines: May have major effect on ability to drive and use machines,
especially at the beginning or change in treatment, in connection with alcohol or tranquilisers.
Undesirable effects: Very common (1/10): dizziness, somnolence, headache, nausea.
Palexia SR only: constipation. Palexia only: vomiting. Common (1/100, <1/10):
decreased appetite, anxiety, sleep disorder, tremor, fushing, diarrhoea, dyspepsia, pruritus,
hyperhidrosis, rash, asthenia, fatigue, feeling of body temperature change. Palexia SR only:
depressed mood, nervousness, restlessness, disturbance in attention, involuntary muscle
contractions, dyspnoea, vomiting, mucosal dryness, oedema. Palexia only: confusional
state, hallucinations, dry mouth, muscle spasms, constipation, abnormal dreams. Other
important undesirable effects: Palexia SR only: drug hypersensitivity (uncommon 1/1000,
<1/100), respiratory depression (rare 1/10,000, <1/1000); Palexia only: respiratory
depression (uncommon 1/1000, <1/100), hypersensitivity (rare 1/10,000, <1/1000).
No evidence of increased risk of suicidal ideation or suicide with Palexia SR/Palexia.
Consult the SmPCs for full details. Overdose: Seek specialist treatment (see SmPCs).
Legal classifcation: POM, CD (Schedule II). Marketing Authorisation numbers,
pack sizes and basic NHS cost: Palexia SR: 50 mg: PL 21727/0041, 28 pack
(12.46) and 56 pack (24.91); 100 mg: PL 21727/0042, 56 pack (49.82); 150 mg:
PL 21727/0043, 56 pack (74.73); 200 mg: PL 21727/0044, 56 pack (99.64)
and 250 mg: PL 21727/0045, 56 pack (124.55). Palexia: 50 mg: PL 21727/0032,
28 (12.46) and 56 pack (24.91); 75 mg: PL 21727/0033, 28 (18.68) and 56
pack (37.37). Marketing Authorisation Holder: Grnenthal Ltd, Regus Lakeside
House, 1 Furzeground Way, Stockley Park East, Uxbridge, Middlesex, UB11 1BD, UK. Date of
preparation: February 2012. P12 0053a.
References
1. Tzschentke, T.M., et al. Drugs Today (Barc), 2009; 45(7): 483-96.
2. Palexia SR, Summary of Product Characteristics. February 2011.
UK/P13 0009. Date of preparation: February 2013.
visit www.palexia.co.uk for more information
Palexia SR (tapentadol prolonged release tablets) is indicated for the treatment of severe
chronic pain in adults, which can be adequately managed only with opioid analgesics
2
Tapentadol is a Controlled Drug, Schedule 2
Start to unlock severe chronic
back pain with Palexia SR
A STRONG ANALGESIC WITH TWO
MECHANISMS OF ACTION IN ONE MOLECULE
1
Adverse events should be reported. Reporting forms and information can
be found at http://www.mhra.gov.uk/yellowcard. Adverse events should
also be reported to Grnenthal Ltd (telephone 0870 351 8960).
GR0042_Palexia_Master_Ad_Pulse_Mag_290x230_AW.indd 1 15/02/2013 16:48
www.pulsetoday.co.uk 36 March 2013 Pulse
DEBATE
VIEWS
Can GPs monitor hospital care?
YES
Dr Robert Varnam
says GPs are well
placed to take on the
Francis Inquiry
recommendation to
monitor the quality
of secondary care
More opinions online
I understand where Robert Francis QC is
coming from, but I dont think it is feasible.
GPs do look at what happens to their
patients when they are admitted. I, for
example, have frequently raised issues
when things have not been done
properly, or raised complaints about
poor care where appropriate.
But he is asking us to do this in a much
more systematic way. This requires
a whole new stream of work and we dont
have any mechanisms with which to
identify these concerns.
This is another example where lots of
work is being put at the door of GPs
without any resources. At the moment
there are no such systems at all in GP
practices. We are totally dependent on,
and only see, the patients discharge letter.
I dont have a problem with rethinking
how GPs define their role maybe it is
something that we need to be concerned
about. But could GP monitoring prevent
another Mid Staffs? Thats just
conjecture, really. The point about Mid
Most of the recommendations from the
Francis Inquiry in the wake of the Mid
Staffordshire scandal were aimed at
national regulators and local hospitals.
However, there are some significant
implications for general practice,
including the proposed duty of candour
legislation and the reminder that both
CCGs and GPs share a responsibility for
improving patient safety.
GPs are well placed to pick up on
some safety issues within hospitals.
This is not about spying on our hospital
colleagues but rather being vigilant for
opportunities to improve patient care.
Two major barriers, though, are time
and confidence in the system. We need to
ensure the forms for recording safety
issues are easy to access and quick to
complete for GPs and our teams. And we
also need to be confident that our safety
reports result in improvement for
patients. Theres no point in taking time
out of a busy day to complete a form if it
doesnt end up benefiting patients.
Evidence shows that people will report
NO
Professor Aneez
Esmail says the
recommendations
are unresourced
and unrealistic
safety concerns if they receive rapid
feedback and can see that effective action
is taken.
These changes are likely to require
a massive increase in the responsiveness
of local commissioners and national
agencies. Im optimistic CCGs will create
a much more cooperative and clinically
led culture between primary and
secondary care. One challenge for many
CCGs will be breaking some of the
traditions in NHS commissioning. In
many areas, commissioning has revolved
around contracts CCGs are in a good
position to take a fresh approach, which
begins with clinical collaboration.
As far as I can see, none of the lessons
from the Mid-Staffs tragedy are new.
The challenge for CCGs and the national
regulators is to put the old lessons into
practice.
Dr Robert Varnam is a GP in Manchester
and clinical lead for primary care at the
NHS Institute for Innovation and
Improvement
Staffs is that no one questioned it, and
the issue is who is best to do that.
It is possible that CCGs should have
that responsiblity, and perhaps could set
up systems to do this. The logical thing
when you talk about monitoring patterns
is that it is going to be the commissioning
groups that need to develop that.
If patients are going to do an exit
interview, which hospitals say they will,
then you might argue that is something
commissoners need to look at when they
make decisions about the hospital.
I would not write the idea off, but
it requires a level of analysis and
sophistication that is quite complex.
We have already got enough to do with
planning and commissioning services,
let alone monitoring them.
Professor Aneez Esmail is a professor of
general practice at the University of
Manchester. His research has focused on
patient safety, including the Shipman
Inquiry
Book prescriptions wont work
without guided support from GPs
Dr Martin Brunet says many GPs are
already offering book prescriptions,
but argues that the campaign still
lacks the practical detail it needs to
take off
pulsetoday.co.uk/brunet
The profession must face up to the
reality of GP burnout
GPs must be honest about the stess
and mounting workload they face, and
should be taught coping strategies,
writes Dr Sara Khan
pulsetoday.co.uk/khan
Debate: will the dementia DES
beneft patients?
Dr Alec Turnbull says the proposed
dementia DES will improve patients
quality of life, but Dr John Cosgrove
argues that case fnding is not enough
pulsetoday.co.uk/DES-debate
CCGs will
create a more
cooperative
culture
between
primary and
secondary
care
This is
another
example of
work being
put at the
door of GPs
www.pulsetoday.co.uk Pulse March 2013 37
H
ow did it happen? The Francis
report on the Mid Staffordshire
hospital scandal is at best
uncomfortable reading,
at worst, horrendous. People
died needlessly because of
poor care. Why?
There has been debate recently about how
useful hospital standardised mortality ratios
(HSMRs) really are. But it is clear that the
rates at Mid Staffordshire were higher than
expected as far back as 2001.
There are multiple problems in pulling
reliable data from existing coding systems.
The trust spent time and money investigating
mortality statistics and wrongly identified
coding errors rather than substandard care as
responsible for the apparently high mortality
rates. Making changes to coding practice was
considered to be the best solution. It wasnt
until 2008 that the Healthcare Commission
launched a full investigation.
But look again and the warning signs were all
there. In 2001, the chief executive of South
Western Staffordshire PCT warned the hospital
leadership was not competent. In January 2002,
a clinical governance review recommended
urgent action over a range of concerns. In 2003,
another review noted inadequate medical
and nursing staffing. Junior doctors had
been removed from position because of
concerns over training. Staff were utterly
demoralised and facing a chronic lack
of manpower. The medical director told
the inquiry a quick walk around the
wards would have shown... there was
cause for concern.
Evidence-based medicine is in my blood.
I like numbers. I like robust proof. But no
matter what the HSMR had been, the
story on the ground was there to be heard. If
patients are left to soil themselves or go unfed,
if staff are demoralised and distressed, this is
what we should have been hearing. That
evidence was there. But who was listening?
People tend to go into medicine or nursing
because they have a desire to do something
useful. So what happens when the professional
culture goes sour? I was thinking about this
today when I caught myself worrying about all
the contract indicators
I was missing. I was
torn between what
would tick boxes and
what would be best for
my patients.
What would happen
if we ditched the
QOF and made
appointments 15
minutes long? What
if we collected the data
we thought clinically
useful, and peer reviewed each other,
supporting ourselves and our colleagues?
What if we asked our patients to help us do
what we said we wanted to do in our interview
at medical school deliver our work as
a vocation?
As the QOF drives its fingernails under the
skin of the consultation, we get further away
from centring what we do on patients. We
look at the computer instead. I hate it. We
have less time to listen, and less time to hear.
This was at least part of the problem in Mid
Staffordshire: numbers mattered more.
The skill of GPs is being squeezed out by the
demands of the contract. We are being pushed
harder to meet tighter targets. But what are
we doing? And who is it for?
The Mid Staffordshire scandal was an object lesson in the danger of
relying too heavily on data and box-ticking, writes Margaret
When listening
matters most
McCartney
A quick walk
around the
wards would
have shown
there was cause
for concern
Dr Margaret
McCartney
is a GP in
Glasgow
Read more of
Dr McCartneys
columns at
pulsetoday.co.uk/
mccartney
38 March 2013 Pulse www.pulsetoday.co.uk
I
ll come straight to the point. Patients:
theyre a bit stupid, arent they? Ive
spent more than 25 years in general
practice waiting for them to up their
game. But Im starting to think its
hopeless.
True, just occasionally they can be
something other than stupid. Take today,
for example. I saw one patient who was quick
and one who was honest. The quick one was
a young woman who, I pointed out, had now
attended twice claiming that her
dihydrocodeine-containing handbag had
been stolen. And yet, I said smugly, Ive never
seen you with a handbag. Thats because
theyve all been nicked, she shot back, which
is smarter and less expletive-riddled than
youd expect from a junkie.
The honest one? A middle-aged man who
phoned about his Viagra. Im afraid theres
a problem at your end, he said. No, I thought,
theres a problem at your end, thats why
youre taking a phosphodiesterase type-5
inhibitor, but carry on. It turned out wed
forgotten to tick the private prescription box
on the computer, so his last few FP10s had
been free on the NHS. Actually, he said, it
was my wife who made me phone, which
put a different slant on the situation, while
rendering him even more honest. And
a bit poorer.
So, some are quick and honest. But
mostly, as I survey the wreckage of the
day, they are stupid. There is, of course,
the low-grade stupidity of glazed-eyed
punters who need me to explain what the
combination of sore throat, runny nose
and cough might possibly add up to,
and who also presumably need
reminding not to stick their
moistened fingers in the plug socket.
And theres the acute-on-chronic stupids,
whose denseness deserves wider
dissemination for posterity. Hence:
Patient 1, a 70-year-old man whos had
a stiff and creaking neck for nine yes nine
months. No prizes for guessing he has cervical
spondylosis. But a gold medal in moronalysis
if you realised his underlying concern, as
MRCGP hopefuls call it, is no kidding
meningitis.
Patient 2, a 28-year-old bloke whos had
a clicky and painful
jaw intermittently for
a year. Self-diagnosis?
Tetanus. My
diagnosis? Slack-jaw.
Where would you
rate these examples,
stupidity-wise, on
a scale of one to
monumental? I dont
mean to be unkind.
I know they dont
have medical degrees.
But Im not a mechanic, and yet if my car
wont start in the morning, I dont
automatically assume its been written off
by a truck, do I?
Its possible, of course, that my perceptions
distorted. Maybe GP attenders are skewed
towards the stupid end of the spectrum.
Perhaps we dont see the sensible ones who
piece together their symptoms intelligently
and decide they dont need to bother a doctor.
Then again, maybe they really are all a bunch
of malingering, neurotic stupids.
And if my appraiser is reading this, a) See
you soon and b) Dont worry that Im showing
signs of burn-out. Ive always been like this.
After a quarter of a century in general practice, Copperfeld has given up
hope that patients will develop any common sense
Im with Stupid,
unfortunately
Dr Tony
Copperfeld is
a GP in Essex.
You can email
him at:
tonycopperfeld
@hotmail.com
CopperfIeld
Presumably
they also need
reminding not
to stick wet
fngers in a plug
socket
Read
Copperfelds
blog at
pulsetoday.co.uk/
copperfeld
or follow him
on Twitter
@DocCopperfeld
Calm skin.
Peaceful night.
Applied regularly, the patient friendly formula of Diprobase
will hydrate, soothe and calm eczematous skin,
1
helping to reduce night-time itching and scratching.
Diprobase Prescribing Information
Please refer to the full SPC text before prescribing this product.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to MSD (tel: 01992 467272)
Code: 02/15 DERM-1069551-0002 Date of preparation: February 2013
Reference: 1. Diprobase Summaries of Product Characteristics, accessed February 2013
Merck Sharp & Dohme Limited, 2013. All rights reserved.
Uses: Diprobase Cream and Ointment are emollients, with moisturising and
protective properties, indicated for follow-up treatment with topical steroids or in
spacing such treatments. They may also be used as diluents for topical steroids.
Diprobase products are recommended for the symptomatic relief of red, inamed,
damaged, dry or chapped skin, the protection of raw skin areas and as a pre-
bathing emollient for dry/eczematous skin to alleviate drying effects. Dosage: The
cream or ointment should be thinly applied to cover the affected area completely,
massaging gently and thoroughly into the skin. Frequency of application should be
established by the physician. Generally, Diprobase Cream and Ointment can be used
as often as required. Contra-indications: Hypersensitivity to any of the ingredients.
Side-effects: Skin reactions including pruritus, rash, erythema, skin exfoliation,
burning sensation, hypersensitivity, pain, dry skin and bullous dermatitis have been
reported with product use. Package Quantities: Cream: 50g tubes, 500g pump
dispensers; Ointment: 50g tubes, 500g tubs. Basic NHS Costs: Cream: 50g tube =
1.28; 500g pump = 6.32; Ointment: 50g tube = 1.28; 500g tub = 5.99 Legal
Category: GSL. Marketing Authorisation Numbers: Cream: PL 00025/0575;
Ointment: PL 00025/0574. Marketing Authorisation Holder: Merck Sharp &
Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU, UK. PI Code:
DERM-1053797-0000 Date of Revision of Text: September 2012
20624 MSD HCP Sleep_Pulse Ad_Jan 13.indd 1 19/02/2013 09:02
NEW LAMA FOR COPD
Date of preparation: January 2013
1. Jones PW et al. Aclidinium Bromide in Patients with Chronic Obstructive Pulmonary Disease: Improvement in Symptoms and Health
Status in the ATTAIN Study. Poster presented at the American College of Chest Physicians Annual Congress, Honolulu, Hawaii, USA,
October 22-26, 2011. 2. Kerwin EM et al. COPD 2012, 9(2):90101. 3. EKLIRA GENUAIR Summary of Product Characteristics 2012.
4. Beier J et al. Thorax 2012, 67: A26-A27. 5. Karabis A et al. Poster presented at ISPOR 15th Annual European Congress, Berlin,
Germany, 3-7 November 2012. 6. Chrystyn H et al. Int J Clin Pract. 2012;66(3):309-17. 7. MIMS September 2012.
Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Almirall Ltd.
Active Ingredient: Each delivered dose contains 375 g aclidinium
bromide equivalent to 322 g of aclidinium. Each metered dose
contains 12.6 mg lactose monohydrateIndication: As a
maintenance bronchodilator treatment to relieve symptoms in
adult patients with chronic obstructive pulmonary disease
(COPD). Dosage and Administration: The recommended
dose is one inhalation of 322 g aclidinium twice daily. Consult
SmPC and package leafet for method of administration.
Contraindications, Warnings, etc: Contraindications:
Hypersensitivity to aclidinium bromide, atropine or its
derivatives, including ipratropium, oxitropium or tiotropium,
or to the excipient lactose monohydrate. Precautions: Should
not be used to treat asthma or for relief of acute episodes of
bronchospasm, i.e. rescue therapy. May cause paradoxical
bronchospasm. Re-evaluation of the treatment regimen should be
conducted if there is a change in COPD intensity. Use with caution
in patients with a myocardial infarction during the previous 6
months, unstable angina, newly diagnosed arrhythmia within
the previous 3 months, or hospitalisation within the previous
12 months for heart failure functional classes III and IV as per the
New York Heart Association. Consistent with its anticholinergic
activity, dry mouth has been observed and may in the long term
be associated with dental caries. Also, use with caution in patients
with symptomatic prostatic hyperplasia or bladder-neck
obstruction or with narrow-angle glaucoma. Patients with rare
hereditary problems of galactose intolerance, Lapp lactase
defciency or glucose-galactose malabsorption should not
take this medicine. Interactions: Although co-administration
with other anticholinergic- containing medicinal products is
not recommended and has not been studied; no clinical
evidence of interactions when taking the therapeutic dose has
been observed. Pregnancy and lactation: Aclidinium bromide
should only be used during pregnancy if the expected benefts
outweigh the potential risks. It is unknown whether aclidinium
bromide and/or its metabolites are excreted in human milk. The
beneft forthe breast-feeding child and long-term beneft of
therapy for the mother should be considered when making a
decision whether to discontinue therapy. Ability to drive and use
machines: The effects on the ability to drive and use machines
are negligible. The occurrence of headache or blurred vision may
infuence the ability to drive or use machinery. Adverse Effects:
Common: sinusitis, nasopharyngitis, headache, cough, diarrhoea.
Consult SmPC in relation to other side-effects. Legal Category:
POM Marketing Authorisation Number(s): EU/1/12/778/002
Carton containing 1 inhaler with 60 unit doses. NHS Cost:
28.60 (excluding VAT) Marketing Authorisation Holder:
Almirall S.A. General Mitre, 151 08022 Barcelona Spain.
Further information is available from: Almirall Limited,
1 The Square, Stockley Park, Uxbridge, Middlesex UB11 1TD, UK.
Tel: (0) 207 160 2500. Fax: (0) 208 7563 888. Email: almirall@
professionalinformation.co.uk
Date of Revision: 09/2012 Item code: UKACL1352 Eklira and
Genuair are both registered trademarks.
Eklira
Genuair
t
322 micrograms inhalation powder aclidinium bromide
Comparable effcacy to traditional
LAMA treatment with twice daily dosing
3-5
Sustained bronchodilation from day 1
1
Improves patients breathlessness
and health status
**
(vs. control)
1
Simple and easy-to-use device
3,5-7
15% annual cost saving vs. tiotropium
7
* Based on the cost of 1 Spiriva
Handihaler
vs. Eklira
Genuair
initiation at month1
Network meta-analysis and phase III study evaluation of
aclidinium vs. tiotropium
** Measured by St Georges Respiratory Questionnaire
Assumes use of 1 Spiriva
HandiHaler
CLOT study.
10
HR: 0.48; 95% CI: 0.300.77; P=0.002; ARR: 8%.
10
ARR: absolute risk reduction. LMWH: low molecular weight heparin. NSTEMI: Non-ST
elevation myocardial infarction. VKA: vitamin K antagonists. VTE: venous thromboembolism,
including deep vein thrombosis (DVT) and pulmonary embolism (PE).
Date of preparation: November 2012. UK/FRA/12/0058. Page 1 of 2
Prescribing information, adverse event reporting
information and references can be found overleaf.
In addition, Fragmin
is a registered trademark of Pzer Ltd. Date of preparation: November 2012. UK/FRA/12/0058. Page 2 of 2
FRAGMIN
(insulin glargine) is indicated for the treatment of diabetes mellitus in adults, adolescents and
children of 2 years or above. Please consult the summary of product characteristics before prescribing,
particularly in relation to side effects, precautions and contra-indications. Legal category: POM. MA
holder: Sano Aventis Deutschland GmbH, D-65926 Frankfurt am Main, Germany. Further information
is available from: Sano, One Onslow Street, Guildford, Surrey, GU1 4YS. Tel: 01483 505515 or the
Sano Diabetes Care Line 08000 35 25 25. Information about this product, including adverse reactions,
precautions, contra-indications and method of use can be found at www.diabetesmatters.co.uk
THE YOU KNOW
101333_Lantus_The_1_You_Know_PULSE_145x230_LANDSCAPE_ad_with_bleed_v4.indd 1 21/01/2013 11:58
necrotising
fasciitis
Emergency medicine consultant Dr Adrian
Boyle discusses the signs, and pitfalls in
diagnosing necrotising fasciitis
Worst outcomes if missed
Death between 20 and 40% of people
with necrotising fasciitis die, despite
surgery.
Disfigurement early diagnosis and
treatment reduces mortality and the
disfigurement from surgery. Delays to
surgery increase the risk of amputation.
Epidemiology
There are about 500 cases of
necrotising fasciitis in the UK each year.
Necrotising fasciitis is more common
in patients with diabetes, chronic
hepatitis and malignancy particularly
leukaemia people who inject drugs and
those who are immunosuppressed.
Necrotising fasciitis can occur because
of infected pressure sores.
It is rare in childhood, but there is an
association with varicella infection.
A GP should expect to see at least one
case in their career.
Diagnosis is frequently made late, after
multiple presentations.
Symptoms and signs
The classic symptoms of necrotising
fasciitis are rarely present initially so
distinguishing necrotising fasciitis from a
M
a
n
d
a
o
a
k
l
e
y
www.pulsetoday.co.uk Pulse March 2013 51
Enjoy in-depth investigation
and analysis of the big
developments in
general practice, plus:
go direct to further
information online
link up your reading with
relevant online CPD
watch our video features
in full
beat the post and read Pulse
as soon as its published
The Pulse iPad app is here
Read Pulse magazine on your iPad
with our free interactive app
All registered members of PulseToday or Pulse Learning can use the app. Simply use your Pulse username and password to log into the app and the latest issue of Pulse will appear
in your Newsstand. If youre not already a member, its free and takes just a couple of minutes to register pulsetoday.co.uk/register
Download the app at
pulsetoday.co.uk/iPad
iPad app 199x130.indd 1 22/02/2013 11:08
cellulitis can be difficult in the early
phases of the disease. Early symptoms
are non-specific:
fever
pain out of proportion to the clinical
findings
inability to use the affected limb.
The limbs are most commonly
affected and the perineum is also
a common site, but any part of the body
can develop necrotising fasciitis.
In patients with fever, clinical
suspicion may be aroused by something
being not quite right for a diagnosis
of cellulitis. The classic cyanotic and
bullous skin changes may only appear
late in the process, but the site of
infection may appear unusual. The pain
may seem too severe for cellulitis, despite
relatively mild skin signs, or there may
be overlying sensory loss. Pain is caused
by tissue necrosis, but the nerves can also
be infarcted as perforating vessels to the
tissues are thrombosed by the necrotic
process. This can cause exquisite pain
and tenderness, but also sensory loss to
the overlying skin. The patient may seem
disproportionately unwell for the degree
of skin involvement. The progression of
the illness can suggest the diagnosis the
patient may seem relatively well initially,
but will deteriorate despite antibiotic
therapy. Crepitus and haemorrhagic
blisters are a late sign.
In patients presenting with pain alone,
the severity of pain and absence of
trauma may suggest the diagnosis.
Differential diagnosis
Symptoms of necrotising fasciitis are
initially similar to the much more
common and benign cellulitis. Patients
with severe musculoskeletal pain may
suggest that their pain is caused by an
assumed or trivial injury.
Investigations
There are no useful investigations that
can be done in primary care necrotising
fasciitis is mainly a clinical diagnosis.
Where there is doubt, prompt surgical
exploration at hospital is probably best,
though MRI or CT scans can be used.
If necrotising fasciitis is suspected,
the patient should be referred as an
emergency. Patients are usually initially
cared for by general surgeons
or plastic surgeons, depending on
local services.
Dr Adrian Boyle is a consultant in
emergency medicine at Addenbrookes
Hospital in Cambridge and an honorary
senior research fellow at Cambridge
University.
Further reading
Sultan HY, Boyle AA and Shepherd N. Necrotising
fasciitis. BMJ, 2012;345:e4274
Five key questions to ask
1 Can you walk or
use the limb?
Inability to use
the limb is
suggestive
of necrotising
fasciitis.
2 Are there any
patches of
numbness?
This would
indicate whether
any sensory
nerves have been
infarcted.
3 Where exactly
is the pain worst?
Pain which is
greatest slightly
distant to an area
of cellulitis is
suggestive
of necrotising
fasciitis.
4 Is the pain
around a wound?
Uncomplicated
wound infections
are not usually
very painful.
5 Are you
feverish and
unwell?
Patients are
usually toxic.
Five red herrings
1 Patients may
attribute limb
pain to a minor
or non-existent
injury.
2 The skin signs
may be relatively
mild at frst.
3 Patients who
inject drugs
often present
without systemic
signs.
4 Patients may
look well in the
initial stages
of the disease,
which can last
a few days.
5 Lymphangitis
is unusual in
necrotising
fasciitis this
usually suggests
a different
diagnosis.
www.pulsetoday.co.uk 52 March 2013 Pulse
s
c
i
e
n
c
e
p
h
o
t
o
l
i
b
r
a
r
y
x
4
pulse-learning.co.uk
Latest
modules
Also new
this month
Guideline debrief
Fertility
2 CPD hours
this case-based learning module uses
primary care case histories to update
you on the Gp-relevant sections of the
new nice guideline
The information
Patellofemoral pain syndrome
0.5 CPD hours
a concise, practical guide to the
pathophysiology, underlying causes,
diagnosis and management of this
catch-all label for knee pain
Key questions
Pre-travel advice
1.5 CPD hours
a travel health specialist answers a Gps
questions including advice on last-
minute vaccines, altitude sickness and
malaria prophylaxis
CKD in primary care
When renal function takes a dip
1 CPD hour
a simple and useful guide to
management of sudden deterioration
of eGFr
Dr Tarun Sharma
Key questions
Asthma
1.5 CPD hours
Very useful module with lots of
practical tips to improve asthma
management
Dr Andreas Photiou
The information
rosacea
0.5 CPD hours
Very good, practical tips useful in
primary care
Dr Krishna Jamuna
Clinical casebook
Addiction
1.5 CPD hours
crisp, clear and concise advice for
front-line use
Dr David Oram
hot topics
End-of-life care
2 CPD hours
incredibly useful round-up of the
palliative care developments relevant
to us in primary care
Dr Matthew Hughes
Practice business
Managing an online appointment
service
1 CPD hour
Very informative, its an eye opener
Dr Maurice Williams
Keep up with all the new modules and online-
only clinical articles by signing up to the weekly
Pulse Education newsletter
pulsetoday.co.uk/emails
Souvenaid
group of companies.
Date of preparation/revision: MO/3141/NOV/12.
UK
Adverse events should be reported. Reporting forms and information can be
found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported
to Medical Information at Norgine Pharmaceuticals Ltd on 01895 826606.
Ireland
Adverse events should be reported to Medical Information at Norgine
Pharmaceuticals on +44 1895 826606.
Reference:
1. Attar A et al. Gut 1999; 44: 226-230.
MO/3213/JAN/13
For the treatment of chronic constipation
macrogol 3350, sodium hydrogen carbonate,
sodium chloride, potassium chloride
www.MOVICOL.co.uk
Blends proven efcacy
1
with fast-mix convenience
MV631_Movicol Liquid_230x290_Pulse_3213.indd 1 03/01/2013 3 Jan 09:42
60 March 2013 Pulse www.pulsetoday.co.uk
Identify
the work
you are not
funded to
undertake
Dr Nigel
Watson
Ten Top Tips
Our expert panel of GPs advises on how to get ready for the
contract changes, CQC registration and the CCG handover
preparing for
April 2013
y
o
u
r
p
r
A
c
T
i
c
e
Identify and reduce excessive
workload
1
All NHS providers of care are
suffering from rising workload and
financial restrictions and to
manage this, many are offloading work
onto GPs. Many practices have reached
saturation point and are struggling to
meet the needs of their registered
population. With major changes to the
GMS contract planned for April, partners
need to audit their existing workload to
discover sources that they feel might be
inappropriate or excessive. Identify the
work that you are not funded to
undertake and then discuss whether this
can be stopped always remembering
your professional responsibilities to your
patients.
Dr Nigel Watson is chair of the GPCs
commissioning and service development
subcommittee, chief executive of Wessex
LMCs and a GP in the New Forest
Prepare for a tougher QOF
2
There are radical changes
proposed for the QOF in the 2013/4
contract. It will become much
more difficult to achieve QOF points and
achieving the top quartile will be very
challenging. Practices will have to
prioritise work.
We have done two things at my
practice. We took a detailed look at the
proposed changes and discussed how
best to achieve QOF points when the new
contract is finalised. We plan to aim for
a broad spread of QOF points without
aiming for the top quartile in most cases.
We also bought an automated blood-
pressure monitor for the waiting room,
which has reduced the burden on staff
time in terms of blood pressure readings
needed for the QOF. We expect it to have
paid for itself in the next year or two.
Dr Adam Jenkins is vice-chair of Ealing,
Hammersmith and Hounslow LMC and
a GP in Greenford, west London
Draw up a 12-month fnancial plan and
put a freeze on hiring new staff
3
Practices should aim to sustain
themselves financially. Before
April, partners and practice
managers should check cash-flow
arrangements. Keep cash in reserve if
you can, and anticipate any impact from
the loss of the MPIG from 2014 onwards.
Staffing is every practices major
outgoing, so dont recruit any new staff
or partners until April. Long-term
commitments leave practices lumbered
if income goes down it is better to be
short-staffed for a few months.
Dr Sella Shanmugadasan is chair of Tower
Hamlets LMC and a GP in Shoreditch,
east London
Negotiate a lease agreement to fx
your service charges
4
In north-east London, a large
number of practices operate out
of healthcare centres, dont have a
contract with the PCT and have disputed
their service charge. Many partnerships
have fallen behind on payments. Its hard
to calculate the service charge but even
harder to challenge invoices if theres no
agreement. We dont know how NHS
Property Services (PropCo) is going to
operate or calculate service charges,
but we cant wait around to find out.
Dr Sella Shanmugadasan
Review all practice policies ahead
of CQC visits
5
GPC guidance on CQC compliance,
which we have been following at
my practice, suggests you review
policies. Then make sure all GPs and staff
know the policies and use them. Our
practice manager takes the lead but
weve also appointed people as leads in
different areas for example, the nurses
lead on infection control. We have also
set up an intranet site so that the policies
and procedures are in one place. We
explained to staff that CQC inspections
are part of an ongoing process. Keep
reviewing policies regularly and give staff
the confidence theyll need when the
inspector knocks.
Dr Richard Vautrey is deputy chair of the
GPC and a GP in Leeds
Ensure compliance with
CQC standards
6
By all means take forward your
plans for the CQC by updating
policies and procedures, training
staff, setting up systems for ongoing
notifications to the CQC, and so on. But
concentrate mainly on ensuring you
meet the necessary standards. If you are
www.pulsetoday.co.uk Pulse March 2013 61
GPs should
help CCGs
to plan
resources
for new
services
Dr Deborah
Colvin
struggling with some of them, prepare
plans to tackle problem areas, with
a realistic timescale and implementation
plan. This will prove to your CQC
inspector you are taking any issues
seriously.
Dr Sobhi Sadek is a GP in Northampton
Ensure your CCG resources GPs
for key work
7
If local commissioners want to run
a new service, GPs should help
them plan resources. In our area
the CCG wanted to run a new records
service for palliative care patients, so we
suggested ways it could be run and
resourced by the CCG through general
practice. Communication and
engagement are key to the success of new
initiatives, and the capacity of partners to
commit to services outside core work.
Dr Deborah Colvin is chair of City and
Hackney LMC and a GP in Hackney,
east London
Research how your practice will be
affected by local cuts and rationing
8
General practice, as ever, will be
expected to pick up the slack and
the bill when cuts are made. We
need to learn to trust what we know and
be prepared to fight hard for it.
This means keeping in touch with
local commissioning strategies, paying
attention to CCG communications and
reading commentaries from other
agencies. We need to be able to respond
to top-down impositions through
lobbying, petitioning the public and
learning about platforms for public
communication. Developing
relationships with local, trade and
national media and employing PR
experts will be key skills. We need also to
forge alliances with local councils as
highlighted in the Lewisham hospital
campaign where the mayor waded in.
Dr Andy Field is a GP in York
Prepare for cuts to local
enhanced services
9
Keep an eye on what is happening
to local enhanced services. Most
will fall under the control of CCGs,
but some will be commissioned (or paid
for) by the local authority, with CCGs or
the NHS Commissioning Board involved
in their detail. The risk is that funding for
some LESs will be stopped. If that is the
case, stop doing the work and raise the
issue with your CCG and LMC. They may
relaunch a LES, or make interim
payments for you to continue the work
while they decide whether to sustain it.
There is a clear opportunity to
renegotiate LESs where they have been
poorly funded or run under onerous
conditions. But if practices are not robust
in their approach to delivery and pricing,
they could find themselves delivering
more and more for less and less. Do your
research and plan which services to
launch, lobby for and pitch for.
Dr John Ashcroft is a vice-chair of
Derbyshire LMC and a GP in Ilkeston
Get to grips with the Any Qualifed
Provider model
10
From April 2013 it will be
up to CCGs to decide when
and where to use AQP as
a commissioning tool. Some practices
will want to bid for new AQP contracts,
but they must be fully aware of the terms.
AQP contracts are based on
competition, not price. The award for
a successful contract is based on the
national tariff. These contracts vary
from the LESs. AQP funding is paid
retrospectively based on the number of
referrals. Even if its a good service, if its
not used there might be less return on
your investment. In that respect, theyre
unlike LESs where you can plan the
finance youll get for undertaking them.
Preparing a pitch takes 40-50 hours or
longer. You will need to invest in staff,
equipment and other resources. You may
also need to rely on co-operation with
secondary and community care. Id
recommend partners look at what AQP
contracts will be available in future, and
research the opportunities and risks.
Dr George Rae is a GPC member and a GP
in Newcastle-upon-Tyne
Go online to
complete CPD
modules on AQP
contracts,
managing your
cash fow and
revalidation
pulse-learning.
co.uk g
e
t
t
y
www.pulsetoday.co.uk 62 March 2013 Pulse
finance diary: March
your practice
As commissioning begins to take shape
ahead of the handover to CCGs in April,
there are increasing opportunities for
GPs to tender for services across a
locality and to bid to run other practices.
It is important to consider the type of
organisation you want to constitute for
the business from the outset.
Tax considerations
Where a business is run through a
limited company or community-interest
company (CIC), the companys profits are
subject to corporation tax at 20% on
profits below 300,000 and currently
24% at the full rate (although this will be
reduced to 21% from April 2014). This is
favourable compared to a partnership or
limited liability partnership (LLP), where
the income coming in as the top slice of
a GPs personal income is subject to
income tax at 45% above 150,000 and
60% on taxable income between
100,000 and 118,410 in 2013/14.
However, if the profits from a limited
company are going to be drawn out as
dividends, then higher-income tax rates
will apply to shareholders who are
higher-rate taxpayers. Income tax and
employers and employees National
Insurance contributions will apply to
directors salaries, making the total tax
charge much higher than would be paid
by a partner or self-employed individual.
Where any spouses or partners who
are basic-rate or non-taxpayers are to be
brought in as shareholders, they should
subscribe for shares from the outset.
Dividends covered by the personal
allowance or basic rate tax are then not
subject to any additional income tax.
Commercial considerations
A limited company, CIC or LLP can be
seen to be more independent than putting
the new business through the main
medical partnership and can provide
a joint venture vehicle if two partnerships
are launching a combined bid. However,
with any new entity, the pre-qualification
questionnaire will require evidence of
financial support and it may be necessary
to introduce capital, whereas an existing
partnership would already have
a financial track record and capital base.
An LLP is effectively a hybrid being,
treated for accounting purposes as an
independent entity, in the same way as
a company with accounts that have to be
on public record at Companies House.
For tax purposes, its members are taxed
as individuals on the profits earned,
regardless of whether they are
distributed or not, in the same way as
partners in a partnership. An LLP does
give limited liability, which can be
attractive in a riskier business.
A CIC is a limited company but it is
also a social enterprise with restrictions
on the profits that can be withdrawn by
the shareholders. This does not prevent
directors remuneration being fully paid
for the services provided by the directors.
Given the reinvestment in the business of
the surpluses for the benefit of patients,
this can give an advantage over
a profit-making company in a tender.
If any shareholders are not doctors,
nurses, practice managers or other
members of the NHS family, then the
company will not qualify as an employing
authority, in which case employees
income would not be superannuable.
This may be advantageous for GPs who
are concerned about the pension cap, but
could be a disincentive for staff. Similarly
an LLP cannot have NHS employing-
authority status.
Valerie Martin-Long is a partner at the
specialist medical accountants PKF, and
can be contacted on 01483 564646 or
valerie.martin-long@uk.pkf.com
Article developed
in association
with
Setting up a new business entity
Valerie Martin-Long on how GPs bidding to run services can best organise their business
Pulse retains
editorial control
of this content
how to avoid becoming
a dysfunctional practice
With tough times ahead, it is vital practices pull together and partners delegate
effectively. Bob Senior advises on the warning signs of problems in store
Tough times lie ahead and teamwork will
be essential if practices are to ride out the
storm. Dysfunctional practices, where
GPs fail to delegate effectively or where
partners fall out, will only make a bad
situation worse.
Unfortunately I have noted an
increasing number of practices where
solicitors have been called in to sort out
partnership disputes (usually at great
expense) or where profits have fallen so
much that partners are deserting the ship.
I have noticed three common signs of
trouble, so if your practice is showing
them, now is the time to change.
GPs who micromanage
Although responsibility for patient care
ultimately rests with the doctors, GPs
have to work as part of a team. Clear
expectations must be established of what
will be done by each team member,
training given, and robust processes
established to ensure work is completed.
GPs should not be permanently
checking up on staff. Nurses need to be
trusted to operate within their remit and
practice managers should be allowed to
get on with running the practice.
Partners not talking to each other
In a busy practice it is not uncommon for
partners to comment that they have no
time to talk to colleagues. This can be
overcome with effort, perhaps by moving
practice meetings occasionally from the
traditional lunchtime slot to first thing in
the morning or in the evening. Unless
partners devote time to the practice they
could find it collapses around them.
But if partners are not talking to each
other because they have fallen out, this
must be resolved. If it isnt, things go
downhill quickly and all partners feel the
effects. In my experience, if partners are
unable to patch things up, one of them
needs to leave the practice promptly.
Allowing the situation to drag on will
mean solicitors have to get involved
further down the line.
No succession planning
Many GPs are struggling to cope with
what is happening now, let alone plan for
the future. But with many now in their
50s and young doctors changing their
attitudes to partnership, practices need
to tackle succession planning now.
Bob Senior is chair of the Association of
Independent Specialist Medical
Accountants and head of medical services
at RSM Tenon
Go online to read
previous Bob
Senior columns
including advice
on managing
premises costs
and preparing for
next years tax
return
pulsetoday.co.uk/
fnancediary
www.pulsetoday.co.uk Pulse March 2013 63
Your practice
Dilemma
One of the GP partners at your
practice sits on the CCG board, while
another fronts a local GP provider
organisation that is planning to bid
for contracts. You are concerned that
the practices internal relationships
might be put under strain during the
bidding process and particularly if
the board does not award contracts
to the partners organisation. How
should you manage this?
Dr Mark Gaffney
The CCG board partner
cannot have any say in
decisions about the provider
How to deal with this will
depend on the individual
characters, but the provider
organisation partner needs
to understand the CCG
board partner cannot have any say in
board decisions in relation to the
provider. I would have an open
discussion with the provider partner and
explain my concerns and expectations.
All GPs on CCGs are potentially
conflicted, simply by their independent
contractor status and ability to develop
outside interests. It becomes more
complex when board members belong to
an external commercial enterprise. That
person may have expert knowledge,
which would be foolish to ignore, but
how do you ensure impartiality?
There are only so many GPs in the UK.
Those with the drive to be entrepreneurs
are likely to be the same people who will
make the boards a success. How do we
harness that? The Committee for
Standards in Public Life published the
seven Nolan Principles as core working
values for anyone who serves the public:
selflessness, integrity, objectivity,
accountability, openness, honesty and
leadership. I would add another
principle for conflicted CCG board
members: absence. They should be
excluded from conflicted items at board
meetings but asked for input at seminar
level where no decisions are taken.
Dr Mark Gaffney is a co-founder and joint
managing director of East Sussex Out
Patient Services and a GP in Eastbourne
Dr Ken Aswani
Recognise that GPs will be
involved in different areas
of work
The partners should have
a full discussion in the
practice to ensure any
adverse fallout is minimised.
The CCG board member
would have to declare a conflict of
interest in any procurement where their
partners organisation is bidding. This
means they are likely to be excluded from
the process.
The partner who leads the provider
organisation will need to accept the CCGs
decision without worrying it was
influenced by their partner. They should
not apply influence to the CCG board
member or other CCG board members
that may be interpreted as unfair.
The other partners will need to
understand the CCG board member must
act on behalf of all its population and
practices, and cannot favour an
individual practice. The lay member of
the CCG, on behalf of the board, will need
to have governance systems to ensure
conflicts of interest do not compromise
decision-making.
As the two partners have conflicts
of interest it is important to have
appropriate partnership agreements,
particularly if there are any financial
arrangements. This would include the
extent to which a partner can have other
provider interests and how these may
financially affect the practice. Additional
time partners spend on outside provider
interests has to be negotiated. CCG
governance and the individuals
professional duty to maintain probity
should be respected, but GPs will be
involved in different areas of work, and
this should not discourage innovation.
Dr Ken Aswani is the medical director at
Waltham Forest Federated GP Consortium
and a GP in Leytonstone
Lynne Abbess
The decision lies outside
the practice it is for the
board to take
Management of conflicts
will become an essential
part of the new NHS.
However in the present
situation, there is nothing
for the practice itself to manage.
The decision is for the CCG board to
take. If there is discussion about the
award of the contract to the GP provider
organisation of which the fellow partner
is a member, the CCG board member
should remove themselves while the
decision is taken.
It is important to distinguish the role
a partner plays outside the practice from
the partnership business. In this case,
the decision has nothing to do with the
partnership. If it is understood the CCG
board member/partner is unable to
influence the decision, that should
prevent difficulties within the practice.
It is also important that partners
appreciate their responsibility lies with
the partnership. If an external activity
presents a conflict, then they will need
to decide which way to jump. It is not
reasonable to expect the other partners
to put up with the challenges from one
GPs external interest.
Lynne Abbess is a partner at Hempsons
solicitors
Now go online to
read this months
other practice
dilemmas:
A Muslim patient
presents after her
brother threatens
her with honour-
based violence
pulsetoday.co.uk/
HBV-dilemma
Should you offer
NHS treatment to
self-funding IVF
patients?
pulsetoday.co.uk/
IVF-dilemma
a confict of interest
between partners
One GP is on the CCG board, the other runs a provider. Three experts advise on
how to avoid a damaging rift within the practice
a
l
a
M
y
64 March 2013 Pulse www.pulsetoday.co.uk
photo essay
your practice
1 Surgery
opening.
Normally
a 7.30am start,
reviewing the
morning
appointments.
2 First
vaccinations
for this baby at
eight weeks old.
3 Home visit. This
patients carer
had been worried
about a sore leg,
but the patient
just needed
reassurance.
4 Arriving for
an A&E shift.
5 The patient
on the trolley
needed a log
roll to clear her
c-spine.
6 Trying to
establish why
this patient had
collapsed at
home.
7 Having a badly
needed fve-
minute break.
View the full series
See all 32 pictures
from this photo
essay online
pulsetoday.co.uk/
weinstein
1
www.pulsetoday.co.uk Pulse March 2013 65
In the documentary photo series
Country Doctor, published in Life
magazine in 1948, photojournalist
W Eugene Smith captured the working
life of a family doctor in Colorado.
Six decades later, photographer
Giovanni Tait and Dr David Weinstein
undertook a similar exercise.
Dr Weinstein works most of the week
as a GP in Brighton, but spends Friday
afternoons as an A&E middle-grade
doctor. I was beginning to feel burnt
out in primary care, he explains.
The balance keeps me sane.
Mr Tait was struck by how his photo
essay echoed the original: Fundamentally
the job has hardly changed.
pulsetoday.co.uk/weinstein
Dr David
Weinstein
A GP and photographer explain the idea
behind their remake of an iconic photo essay
that followed a family doctor in the 1940s
2 3
4
5 6
7
www.pulsetoday.co.uk 66 February 2013 Pulse
online
your practice
Editors
choice
From the
latest
practice
business
and
working
life
articles
online
Better end-of-life care
Dr Damian Patterson on how his practice
got gold-standard accreditation
pulsetoday.co.uk/GSF-casestudy
A GP for the homeless
Dr Nigel Hewett explains why he chose
to work with this vulnerable group
pulsetoday.co.uk/nigel-hewett
Reducing workload
Dr Masood Nazir makes 10 suggestions
to save time on admin and meetings
pulsetoday.co.uk/saving-time
Online appointments
1 CPD hOuR Dr Osman Bhatti explains
how to enable online booking
pulsetoday.co.uk/onlineappointments
Last-minute QOF tips
Dr Simon Clay covers exception coding
to help practices gain maximum points
pulsetoday.co.uk/lastminute-qof
Software to cut errors
Dr Sarah Rodgers guide to a new
plug-in to cut script errors
pulsetoday.co.uk/PINCER-guide
a
l
a
M
y
x
2
/
g
e
t
t
y
/
j
u
l
i
a
N
C
l
a
x
t
O
N
x
2
Gps prefer
pulse learning
96
%
94
%
91
%
83
%
rate Pulse
Learning higher
than any other
CPD site
would
recommend
Pulse Learning
to their GP
colleagues
say Pulse
Learning has
changed their
day-to-day
practice
have already
decided to
renew their
premium
membership
Based on a survey of 732 Pulse learning members carried out in December 2012.
Dont get left behind, join now at
pulse-learning.co.uk
Premium members have exclusive access to over 400 clinical,
practice business and commissioning CPD modules
11835P Pulse 290x230 Advertorial_Mar '13.indd 1 15/02/2013 16:40
68 March 2013 Pulse www.pulsetoday.co.uk
RECRUITMENT
Do you really want to make a difference?
We are currently looking to recruit:
Salaried GP/Nurse Practitioner
Avicenna Medical Practice
Bradford, West Yorkshire.
Full time/ part time
Highly motivated GPs and/or Nurse Practitioners who are committed to
providing and developing high quality clinical services with the full support
of our extensive team of experienced GPs.
We will particularly welcome applications from GPs and/or Nurse
Practitioners with an interest in personal development/GPwSi services is
desirable though not essential.
Investors in People GOLD Standards accredited and a finalist in HSJ
Workforce Development Award 2010
Further information or to apply please contact:
Sarah Rhodes, Practice Manager Tel: 01274 664464/07837004309
sarah.rhodes@bradford.nhs.uk
Avicenna- SINGLE UNIT_Avicenna- SINGLE UNIT 15/02/2013 10:05 Page 1
Growing PMS practice in South West London
seeking for a part time 4 session initially
and likely to become
A full time salaried partner.
High QOF achievement.
Paper light EMIS Web system.
Team of 2GPS & 2 Practice nurses.
Medical student teaching
A knowledge of Tamil language would be an advantage.
Salary negotiable.
Please send or email CV with covering letter to
Tina Bowles, at tinabowles@nhs.net
Gunasuntharam- SINGLE UNIT_Gunasuntharam- SINGLE UNIT 21/02/2013 10:59
Beechfield Medical Centre
Beechfield Gardens, Spalding, Lincolnshire
Salaried GP but would consider Partnership
(6- 9 sessions)
What can we tell you about ourselves?
New purpose built premises in busy market town
Friendly and supportive working environment with excellent nursing
and admin teams
Part dispensing
List size 14,500 and growing
6 Partners
EMIS LV - moving to EMIS Web
High QOF achievement
Active involvement in Clinical Commissioning
GU and FP clinic
www.beechfieldmc.co.uk
Start date May/June but this is flexible for the right candidate. Rate of
pay dependent upon skills and experience. Informal visits and enquiries
welcome.
Apply with CV to:
Grant Scott, Practice Manager, Beechfield Medical Centre, Spalding,
Lincs. PE11 1UN or
email grant.scott@lpct.nhs.uk for more information.
Closing date: 29 March 2013
BEACHFIELD -DOUBLE UNIT_BEACHFIELD -DOUBLE UNIT 11/02/2013 16:01 Page 1
Mastercall Healthcare
Mastercall Healthcare is an established award winning provider of
urgent unscheduled and scheduled primary care services.
SESSIONAL GPs
We are looking to enhance our existing team of sessional GPs at our
Stockport and Trafford Health Centres. We are looking for patient
focused, innovative, flexible and enthusiastic GPs in both our out of
hours service and GP-led walk-in centre.
Successful GPs will enjoy integrated and flexible working patterns
developing a high quality primary care service for the people of Stockport
& Trafford.
GPs will benefit from a robust clinical governance infrastructure and a
range of professional training and development opportunities to enhance
their continued professional development in primary care and enhance
their appraisal portfolio.
Excellent benefits including competitive rates of pay plus NHS
superannuation. MRCGP is desirable. We give full training in telephone
consulting skills. A variety of shifts are available during in-hours, out of
hours and overnights on a sessional basis.
To apply please send your CV to Jenny Abbott, HR Manager at
abbottj@stockport-pct.doctorscoop.nhs.uk or telephone 0161 476 7006
for further information.
Mastercall Healthcare is an Equal Opportunities employer.
Mastercall -DOUBLE UNIT_Mastercall -DOUBLE UNIT 21/02/2013 11:23 Page 1
Partner or Salaried GP required from July 2013
Due to retirement of full-time (8.5 sessions per week) Partner,
we seek a committed, flexible GP to join our friendly,
democratic 6 partner Practice on the eastern edge of Derby.
We are happy to consider full and part-time applicants.
12,000 patients
2 sites (Spondon Village & Chaddesden)
High QOF achievement and Patient Satisfaction
TPP SystmOne, paper light
Opportunity to train medical students
CV and covering letter please by 31st March to
Wayne Pitcher, Practice Manager, Dr Gates & Partners, Chapel Street
Medical Centre, 10 Chapel Street, Spondon, Derby, DE21 7RJ
Informal enquiries and visits welcomed, Tel 01332 680521,
email wayne.pitcher@nhs.net
DR GATES- SINGLE UNIT_DR GATES- SINGLE UNIT 21/02/2013 11:04 Page 1
Full Time Slaried GP Post
Salary 90,000
Coastal Health Care Ltd
In the Fleetwood Area.
Scheduled and Unscheduled Care options available.
Do you want to be involved in a dynamic organisation delivering
a variety of healthcare across the Lancashire Coast?
Innovative and high quality GP required to work in scheduled
and unscheduled care environment.
Flexible working hours
No overnight commitments
6 weeks annual leave
For an information pack, Job Description and
Application form please phone 01253 655552
Monday - Friday 09.00 - 16.00 only.
Closing date 8th March.
COASTAL- SINGLE UNIT_COASTAL- SINGLE UNIT 18/02/2013 10:11 Page 1
www.pulsetoday.co.uk Pulse March 2013 69
HANWORTH MIDDLESEX :
SALARIED GP
up to 8 sessions pw. PARTNERSHIP PROSPECTS.
We require a Doctor who will provide high standards of care and
contribute to the development of this innovative Practice
Approx 4000 patients.
Modern purpose built Medical Centre
TPP SystemOne. High QOF Achievment.
Friendly dedicated Practice team including Nurse, HCA
Application with CV to s.winayak@nhs.net
Sheena Winayak , The Medical Centre, 192 Twickenham
Road, Hanworth, Middlesex TW13 6HD
MEDICAL- SINGLE UNIT_COASTAL- SINGLE UNIT 21/02/2013 10:51 Page 1
PERTHFECT
If there was ever an ideal destination for qualied doctors, its
Perth. Exciting opportunities, great salaries, an outdoor life-
style, warm weather, a warm welcome everything you could
wish for, youll nd here in the capital city of Western Australia.
If Perth is the place for you, we can help you make the perfect
move by sorting out all the paperwork and administration.
For more information, contact Mairead at Locumotion.
Email: mdonovan@locumotion.com Phone: 01 299 3550.
www.locumotion.com
LOCUMOTION -DOUBLE UNIT_LOCUMOTION -DOUBLE UNIT 14/01/2013 10:13 Page 1
Cappadocia, Turkey, boasts one of the most unusual
landscapes in the world with its "fairy chimneys"
arising from canyons and its underground cities. Join
Conference Plus in this unique location for a truly
stunning backdrop to Continuing Medical Education
of the highest quality.
Cappadoc|a,Istanbul & 8odrum
Seville, the capital of Moorish Spain, and even better
when combined with the magnicent Alhambra on
our Granada extension. Wonderful sights, fantastic
dining and a day trip to mediaeval Cordoba all
arranged around our academic programme of
obstetrics, orthopaedics and gastroenterology.
Sev|lle,Cordoba & Granada
Discover the breathtaking scenic beauty on this tour
of Peru, exploring the Amazon basin whilst learning of
the medicinal properties of the ora, the White City of
Arequipa, the magnicent Condors and hot springs at
Colca Canyon. At Lake Titicaca we will hold clinics for
its island communities. All tours based around a
varied and enlightening academic programme.
The Amaton, a Peruv|an adventure
Book online at: www.conferenceplus.co.uk
or email: info@conferenceplus.co.uk
Tel: 01923 859363
28th May - 1st June 2013
8th - 12th October 2013
12th -26th October 2013
Relain
Keval|dat|on
Arranging high quality education in the world's most exciting destinations it
K
in la el Re
& l u b n a t s I , a | c o d a p p a C
m e h t f o e n o s t s a o b , y e k r u T , a i c o d a p p a C
s ''s d lld rrl o wwo e h tth n iin n o iio tti a cca u ddu e y tty i lli a ua q h gg iig h g nng iin g n aa rra rrr A
d | l a v e KKe
Ke
ii in i a a l e R
t s 1 - y a M h t 8 2
t a
m u r d o 8 &
l a u s u n u t s o m
n iin tti s ees dde dde
n
g ng iin tti iit cci xxc eex t s o m s ''s
n o | t a d
3 1 0 2 e n u J t
A h T
d a n a r G & a b o d r o C , e l l | v e S
e t n e o r t s a g d n a s c i d e a p o h t r o , s c i r t e t s b o
m a r g o r p c i m e d a c a r u o d n u o r a d e g n a r r a
d r o C l a v e a i d e m o t p i r t y a d a d n a g n i n i d
h g i s l u f r e d n o W . n o i s n e t x e a d a n a r G r u o
A t n e c i n g a m e h t h t i w d e n i b m o c n e h w
n a , n i a p S h s i r o o M f o l a t i p a c e h t , e l l i v e S
. y t i l a u q t s e h g i h e h t f o
d e M g n i u n i t n o C o t p o r d k c a b g n i n n u t s
n o i t a c o l e u q i n u s i h t n i s u l P e c n e r e f n o C
u o r g r e d n u s t i d n a s n o y n a c m o r f g n i s i r a
c y r i a f " s t i h t i w d l r o w e h t n i s e p a c s d n a l
m e h t f o e n o s t s a o b , y e k r u T , a i c o d a p p a C
t c O h t 2 1 - h t 8
a d
. y g o l o r e
f o e m m
l l a a b o d
c i t s a t n a f , s t
n o a r b m a h l A
r e t t e b n e v e d
n o i t a c u d E l a c i
y l u r t a r o f
n i o J . s e i t i c d n u
" s y e n m i h
l a u s u n u t s o m
3 1 0 2 r e b o
| v u r e P a , n o t a m A e h T
g o r p c i m e d a c a g n i n e t h g i l n e d n a d e i r a v
a d e s a b s r u o t l l A . s e i t i n u m m o c d n a l s i s t i
h l l i w e w a c a c i t i T e k a L t A . n o y n a C a c l o C
d n a s r o d n o C t n e c i n g a m e h t , a p i u q e r A
h t , a r o e h t f o s e i t r e p o r p l a n i c i d e m e h t
h w n i s a b n o z a m A e h t g n i r o l p x e , u r e P f o
t u a e b c i n e c s g n i k a t h t a e r b e h t r e v o c s i D
c O h t 6 2 - h t 2 1
9 1 0 : l e TTe
c @ o f n i : l i a m e r o
w w : t a e n i l n o k o o B
e r u t n e v d a n a
. e m m a r g
a d n u o r a
r o f s c i n i l c d l o h
t a s g n i r p s t o h d
f o y t i C e t i h W e h
f o g n i n r a e l t s l i h
r u o t s i h t n o y
3 1 0 2 r e b o t
3 6 3 9 5 8 3 2 9
k u . o c . s u l p e c n e r e ffe n o c
k u . o c . s u l p e c n e r e ffe n o c . w w
CONFERENCE PLUS -DOUBLE UNIT_CONFERENCE PLUS -DOUBLE UNIT 29/01/2013 13:39 Page 1
URGENT CARE -DOUBLE UNIT_URGENT CARE -DOUBLE UNIT 07/01/2013 12:5
Book your appointment now!
enquiries@nzlocums.com | www.nzlocums.com
Positions in New Zealand...
We can provide:
FREE comprehensive recruitment service
Exciting GP opportunities
Immigration assistance
Were visiting London! Book your personal
consultation from 30-31 May at NZ High
Commission, 80 Haymarket, London.
NZLocums- SINGLE UNIT_NZLocums- SINGLE UNIT 21/02/2013 11:13 Page 1
www.pulsetoday.co.uk 70 March 2013 Pulse
Peverley
B
ack in the day, we used to be
an all-male practice, and
consequently I was as au fait
with the complexities of the
menstrual cycle as any GP in
the country. Im not saying
I enjoyed dealing with these endless problems
(who does?) but I could handle it fairly well
and even managed to look as if I cared, quite
a lot of the time.
Now the demographics of general practice
have changed for the better. Pretty much
every practice, including ours, has a couple of
Nice Lady Doctors to deal with all this tedium.
My total freedom from exposure to the
menstrual diary comes at a price, however.
The reception staff have identified another
type of patient who they think might best be
dealt with by me. Every time some swivel-eyed,
sweating sociopath with benzo-hunger in his
eyes rocks up to the front desk at ten to six,
they say: Aha! Another one for Dr Peverley.
The reason for this (apart from me being
six foot three) is that I tend to judge people,
and act on those judgments. Were not
supposed to do this; non-judgmentalism is
a touchstone of our times. But if someones
behaviour is in my opinion self-destructive,
anti-social or detrimental to other
individuals or society in general, I will
generally tell them. Of course, these days,
you cant write worthless parasite in the
medical records, so my notes are littered
with phrases such as this patient is
disabled by inherent moral perplexity.
Well, I know what it means.
One such prize specimen joined our
practice and handed in his repeat
prescription to be filled. When he came
in, it was immediately obvious that his
walking stick was more of a badge of
entitlement than a mobility aid.
My old doctor wasnt giving me what
I needed, he explained. That may or may
not have been true, but after looking at his
prescription, it was certainly the case that his
old doctor had been giving him what he didnt
need. Shampoo? I asked sweetly. Ive got
a scalp condition. I had a quick look. No you
havent, I pointed out, and the black line went
through that one.
I dont want to know
why you were getting
toothpaste on
prescription, but youre
not getting it from us.
Another black line.
Have you got gluten
intolerance? Whats
gluten intolerance?
Never mind that just
now. But youll not be
needing all this bread,
pasta and biscuits from now on.
Then we (well, I say we...) decided that the
morphine, tramadol and diazepam werent
really appropriate for a 23-year-old with a bad
back (investigations all normal) so they went
too. So did the protein drinks, because by now
I was on a roll.
I need a sick note for the disability, was his
next try. What diagnosis shall I put on it? Oh
anything, I dont mind. I think Ill wait for your
records before I issue anything of that nature.
I handed him his new repeat prescription, now
comfortably fitting on one side of paper, and he
looked at it with disbelief: Wheres all me gear?
Im gonna f*ckin complain about you!
He got up to storm out. Youve forgotten
your stick, I told him.
Every now and then a scrounger of the frst order shambles into
Phils consulting room, and hes not afraid to give them both barrels
Sticking it to the
malingerers
Dr Phil Peverley
is a GP in
Sunderland and
was PPA and
BSME columnist
of the year in
2012.
Read more
Peverley
columns at
pulsetoday.
co.uk/peverley
Of course, these
days, you cant
write worthless
parasite in
the medical
records
J
o
u
r
n
a
l
:
P
u
l
s
e
D
e
r
m
a
l
:
D
e
r
m
a
x
R
o
c
k
e
t
A
d
S
i
z
e
:
2
9
0
x
2
3
0
m
m
B
l
e
e
d
:
3
m
m
S
u
p
p
l
y
a
s
h
i
-
r
e
s
P
D
F
J
o
b
N
o
:
2
2
9
3
5
LIFT OFF
FOR SCALY SCALPS
Dermax Therapeutic Shampoo. Benzalkonium chloride 0.5% w/w.
Uses: For the topical treatment of pityriasis capitis and other
seborrhoeic scalp conditions, where there is scaling and dandruff.
Directions: Adults, children and the elderly: Wet the hair. Apply a
liberal quantity of the shampoo to the scalp and, with the tips of
the fingers, rub in thoroughly. Rinse. Repeat the application and
massage to produce a rich lather. Remove as much lather as possible
with the hands, before rinsing thoroughly under running water.
Contra-indications, warnings, side-effects etc: Please refer to
SPC for full details before prescribing. Do not use if sensitive to any
of the ingredients. Keep away from the eyes. No known side-effects.
Package quantity, NHS price and MA number: 250ml bottle 5.69,
PL 00173/0198. Legal Category: MA holder: Dermal Laboratories,
Tatmore Place, Gosmore, Hitchin, Herts, SG4 7QR. Date of
preparation: February 2012. Dermax is a registered trademark.
P
dermax.co.uk
Adverse events should be reported. Reporting
forms and information can be found at
www.mhra.gov.uk/yellowcard. Adverse events
should also be reported to Dermal.
Therapeutic Shampoo
benzalkonium chloride
Lift and clear with
22935_Dermax Rocket Ad_FULL PI_Pulse_AW:1 31/1/13 09:48 Page 1
LAMA = long-acting muscarinic antagonist.
References: 1. SPIRIVA
18 g Summary of Product Characteristics. http://medicines.org.uk/emc. Accessed August 2012. 2. Tashkin DP et al. for the UPLIFT Study
Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:15431554.
Prescribing Information (UK) SPIRIVA
(tiotropium)
Inhalation powder, hard capsules containing 18 microgram tiotropium (as
bromide monohydrate). Indication: Tiotropium is indicated as a maintenance
bronchodilator treatment to relieve symptoms of patients with chronic
obstructive pulmonary disease (COPD). Dose and Administration: Adults
only age 18 years or over: Inhalation of the contents of one capsule once
daily from the HandiHaler